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PREFACE
This dissertation describes the research performed in two major areas of
dermatopharmaceutics: in vitro transdermal permeability studies and in vivo topical
toxicity studies" The scientific focus was on the permeability studies and thus represents
the majority of the results presented here as well as the focus of the discussions both
preceding and following the data. The experimental design of the permeability studies
is congruous (unless noted) with guidelines published as a result of a Food & Drug
Administration (FDA) and American Association of Pharmaceutical Scientists (AAPS)
workshop on principles and practices of in vitro percutaneous penetration studies (Skelly

et ai, 1987)" For scientific continuity, it is desirable for all researchers in this field to
adopt these guidelines"

It is equally important to adopt consistent, well-defmed

terminology related to the field" This dissertation provides a comprehensive glossary of
terms used in the text.. It may be beneficial to review the terms prior to reading the body
of the text..
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ABSTRACT

_~L""_"'''''''

transdermal drug delivery systems are . . . . . . . . . . __ to delivery,

diffusion, of a few substances exhibiting natural
_

....._

These substances are

highly potent agents possessing a

philicity.. These limitations are dictated by

as well as

corneum, which acts as a barrier..

.t'<Ii'''II'·''''li''''llH'''''''

In order to expand

,U'''................~

_.t'<IJf'\

outermost layer

stratum __. . . . . ._'...... "'. .

The barrier strength of keratin is attributed to

protein . . . ._A ...."""'.. ..
bond ........

.......... "1

.....

passive

...........,,11 ... ..,.............

the
Jl"'''_o.lI~4.

extensive _.....,_. . . . ,..__

spectrum of transderrnal drug candidates

keratin barrier must be overcome .
Low . ..Il.l._.IL~\

... JI. ........

cystine

weight primary aliphatic thiol compounds reduce -.. . . .

,_.L.III.,.L_ _

in the keratin

thus diminishes the number

forming sulfhydryl-terminated
cross-links between polypeptide chains..

shown to increase the permeability of the skin to a variety of drugs

Iinkages

units and
has been
opening up the

stratum corneum for facile diffusion most probably through increased
validates the use of low molecular weight primary aliphatic thiol compounds as
UQll,."'"' ' ' ' ' '.A. . .

,lAM4.

One
!l'T1i"II1IT1Iro,I"lIT"Ii'lf"

permeation enhancers .
the major requirements of any pharmaceutical applied topically is lack of

irritation that would _"'' ' __. . the formulation unacceptable to the user..

An

acute non-invasive dermal toxicity study on both animals and humans has shown most
the enhancers to be well tolerated.
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Introduction
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1.1 Transdermal Drug Delivery
Transdermal drug delivery
into the bloodstream
contrast

the process

the goal

eliciting a systemic pharmacological effect. In

ointments which are messy and difficult

creams

a discreet device sometimes

accomplished

administering drugs through the skin

active ingredient and provides its controlled

1II"~T"'!:lIL_t:.l>AI"II

apply,

process

to as a "patch" that houses the

release~

relatively concentrated drug is driven by the concentration gradient
into the systemic circulation.

the "'_",,,,JLIl

Although patches can be manufactured to

effective for weeks or months, current patient acceptability is for 24 hour dosing with
a disposable patch.

Advantages of Transdermal Drug Delivery
Until recently,

therapy was restricted to repeated

forms which are difficult to apply uniformly
Transdermal drug delivery provides controlled release
periods
valuable

_I>JJ... 1U......" ..... ,."A

insure reproducible
the active

over extended

time thus significantly reducing the frequency of dosing.

is extremely

drugs with short half-lives, where the elimination of the inconvenience of

frequent dosing substantially improves patient compliance. Zero-order controlled release
also avoids fluctuations in blood levels seen with intermittent dosing.. Fluctuations into
the

are the most common cause of adverse drug reactions.. For this reason
release

important for drugs with a narrow therapeutic range .
administration avoids a multitude of problems encountered with

drugs administered orally. Poor or uneven oral absorption will cause undesirable

4
""AA""'........"'_

and various

1.

are also subjected

effective
remove
termination of therapy
simply

Drug Delivery

a
corneum

an
are

a

11. .. 11 .....' - ' " - _

a

5

the tightly packed

£ .... _£.1,;1.""'-......

the stratum corneum

structure

within a reasonable time (Guy
delivered

Due to limited diffusivity, only potent drugs can be

transdermally.. To a certain extent, the total quantity of drug diffused can be increased
by increasing

size of

patch; but patient

limits the

to about 30 cnr .

coated cells of protein and water of the stratum corneum demand

drug possess

partitioning

the

of

both lipophilic and hydrophilic attributes for adequate penetration (Michaels 1975,

Drugs that bind significantly to skin proteins are difficult to deliver transdermally
(Kelly 1985) . This effect may be overcome by designing the patch in a such a way as
to deliver an initial priming or loading dose to saturate these binding
....... 4.&.A.... ""'"

drugs and drugs that bind

the skin proteins tend to stay in the

stratum corneum causing what has come to be known as the "reservoir effect".. The
problems associated with this phenomenon are long lag times (time to therapeutic
response) and continued systemic drug input after removal of
_"' . . ."',. . , absorbed, some biotransformation in the skin
layers of

dosage
occur

$

The underlying

epidermis do show some metabolic activity albeit limited (Kermici
Drug stability could be compromised before systemic activity occurs .

The application site is important. Significant differences exist in the structure and
physicochemical properties of the stratum corneum between individuals and between skin
In

same person (Southwell 1984) .

Drugs and excipients may

primary local irritation at the

of application.

6
with even slight

of

population.

problematic in
".n"'~l"""''''.''''''' seen clinically with

smaller, more porous systems (Moore
bacteria

systems
were not of a
-'

early transdermal drug

but due to sweat accumulation and

irritation

."A~"A_A

1988)~

systems

allow

by-products

been stated that more
cannot be
without the use·

..... A-1;4. ...

~

into a transde·rmal

permeation enhancement (Pfister 1990).

1.4 The Transdermal Delivery Site
skin consists of two distinct but mutually dependent tissues: the avascular

is a watery, porous, nonselective

epidermis and underlying dermis.
fluid - filled connective

matrix intertwined with a dense capillary network.

a multi-laminate structure divided into four separate

epidermis

stratum granulosuffi, stratum spinosum, and stratum germinativum. A fifth
but is seen clearly only
(palm)

...., ..... 1

JJL~

..

(Montagna 1974). The

are

as the

corneum are metabolically """' . . . . _. .

.L

outermost
... "....,>ul.AJUL

or horny

of

the

(foot)

palmer

epidermis, excluding the stratum
since the cells of the stratum

Figure 1 illustrates a cross section of typical skin.

the epidermis exposed to the environment is the stratum
averages about 10 to 20

flattened, dense, metabolical1 y

thick and about 10 to
known as

7

Figure 1: Cross-sectional diagram of human skin. The
arrows depict potential drug entry routes (Montagna 1974).

corneocytes (Holbrook 1974, Bronaugh 1982) . They are arranged in a brick-like fashion
and are individually surrounded by a complex lipid material.

Since the cells are not

attached to each other it is believed that the lipid material acts as a cement to hold the
structure in place analogous to the structure of a brick wall (Schaefer 1988). About 20%
of the stratum corneum is lipid material, about 40% is keratinized protein and 40% is
water in normally hydrated skin (Kelly 1985, Ritschel 1988). Corneocytes contain large
quantities of the protein keratin.
Keratin protein exists as ordered a-helical strands embedded in a less well-ordered
globular matrix consisting predominately of the amino acid cystine. This high cystine
content is specific for keratin (Gershon 1972). Cystine is the only amino acid capable

8

of forming disulfide linkages and one of only two amino acids containing sulfur.. It
seems the only pu1J>Ose of this amino acid is to provide structural linkages (Montagna
1974). The functions of disulfide bonds can be categorized into providing structural
stability, mechanical strength, and chemical stability"

1.4.1 Structural Stability
The primary function of disulfide cross-linking seems to be that of keeping the
skin structure intact. Keratin fibers can undergo great elongation, up to 100% in water,
and still exhibit full recovery, if the extensions are done under conditions that minimize

cross-link: scission (Menefee 1977). Cross-links stabilize the a-helical structure.. When
disulfide cross-links are reduced, the stability of the helical protein chains decreases
(Menefee 1965). The extent of sorption of liquids is determined by cross-link density.
Disulfide content correlates well with degree of maximum swelling (Caldwell 1970) .

1.4.2 Mechanical Stability

If the disulfide bonds in keratin are progressively decreased, regular changes

appear in most standard mechanical strength tests such as Young's modulus, torsional
modulus, yield points, br

strength, and elongation to break (Feughelman 1964,

Crewther 1965, Chapman 1969). Those properties involving high strain are usually most
affected by cystine levels (Menefee 1977) . The stratum corneum provides almost totally
the mechanical strength of the epidermis (Scheuplein 1971).

9
1.4.3 Chemical Stability
Disulfide cross-links provide remarkable barrier properties
corneum..

the stratum

cells differentiate and migrate to the surface, they undergo extreme

densification and cross-linking thus imparting a chemical

and impenetrability

for most all compounds even with widely differing properties (Matoltsy 1976, Tregear
1964).
IS

well accepted that permeation through the stratum corneum is the

rate-limiting step

transdermal absorption and has been proven so over the years

(Treherne 1956, Scheuplein

Shaw 1976, Flynn 1981).. The stratum corneum

dense and compact with diffusion mechanics similar to transport through solids.. In
contrast, the dermis, consisting

fluid filled interstices, allows for liquid-type diffusion

accounts for a permeability increase of four orders of magnitude over the stratum
corneum with a series of compounds with varying lipophilicity (Schueplein
"'-" ....... ,....,.A.

layers

the epidermis and especially the dermis are relatively more significant

barriers to penetration of nonpolar molecules than of polar molecules due to
aqueous environment, but they are still insignificant compared
stratum corneum..

the barrier effect of the

These layers represent only about 4 % of the total diffusional

resistance (Barry 1983).

1.4.4 Variations in Permeability
Variation between individuals has marked clinical significance.
"' ....!I.1""!!, .....u •••A.

is always

than intra-specimen variation (Southwell 1984).. Variations in permeability of

human stratum corneum both from person-to-person (and within each person) has been

1I"A~n1l"t~3i;i'1

to be influenced by a complexity of

include

blood supply, skin temperature; individual

sex,

' J r '. . ,w-..,,-lL.'

such

stratum

corneum turnover time, appendages, thickness, packing, number
density; environmental factors such

and

mechanical stress and exposure; and

variables such as composition (lipid, protein, and water), enzymatic

and

of disulfide

has yet to

All of these
have been shown to

the
of the

_-IkJL",,--

_A"" ..._A .....

to various solutes

(Feldmann 1967, Anderson 1973, Montagna 1974, Kermici

varyIng

Weigand 1980, Elias 1981, Barry 1983, Southwell 1984, Walters 1986, Berardesca
1988)..

number of these variables, some of which may be insignificant relative to

others, are discussed

more detail in

following sections .

1.4.4.. 1 Potential Variables Which Influence Permeability
It is important to note that these are generalized statements of which there are
and provisos.. These variations pertain to normal, non-diseased skin"

1.4.4.1.1 Age

from a

The intrinsic permeability of skin shows

variation, relative to other variables,

hours after birth to extreme old

ultrastructure of the stratum

corneum in a newborn is indistinguishable from that of an adult (Walters 1986) .

1.4.4.. 1.2 Sex
is no information to suggest permeability differences between the sexes"

11
Any

differences that may occur are insignificant relative

variation among

individuals (Walters 1986).

1.4.4.1.3 Race
The stratum corneum of blacks has the same thickness as whites but the density
of the corneocytes and number of cell layers is significantly greater (Weigand 1980) .
This leads to greater barrier effect in terms of solute permeation. This difference could
lead to specific race-oriented transdermal pharmaceutical products (Berardesca 1988).

1.4.4.1.4 Blood Supply
The blood supply rises up into the dermis but not the epidermis. The vessels
penetrate to within 150-200 I'm of the skins surface (Idson 1975).. From the point of
view of standard cellular metabolic need, the skin is vastly overperfused" Estimated
minimum flow requirement for cellular respiration is about 0 . 5-1 . 0

ml tissue.

The mean cutaneous flow is some 20-30 times greater than this minimum

maximum

flow can be more than 100 times (Barry 1983)..

The physiological reason for

phenomenon is the use of the cutaneous vascular system as the prime regulator of total
body temperature" In fact, human skin is so rich in blood that it can store as much as
4. 5

of the total blood volume (Montagna 1974)" The skin receives 33% of the average

cardiac output (Szycher 1986).. This immense volume and turnover rate results in no
inter-individual differences in permeability due to blood supply and is ideal for systemic
drug delivery via the transdermal route.. Also, for any transdermal system, it is unlikely
that uptake by the micro-circulation of the skin would be rate-limiting .
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HYDROPHILIC
LIPOPHILIC

Figure 2: Cross-sectional diagram of human
epidermis with arrows depicting the hydrophilic
and lipophilic pathways (Montagna 1974).
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STRATUM I VIABLE
CORNEUM EPIDERMIS

DELIVERY
SYSTEM

o

[£J

B

D

[IJ

DERMIS

o

LEVEL OF DRUG INPUT

.....

h

~

DISTANCE
Figure 5: Concentration vs. distance diagram of the physicochemical processes of
transdermal drug delivery.

The series of events of transdermal drug delivery is governed by system design,
physicochemical principles, and physiological state.

Pharmaceutical scientists have

difficulty controlling the physiological state of the patient, cannot change the
physicochemical laws of nature, and therefore have only their ability to improve drug
delivery system design as their means to a pharmacologic goal.
Specific system modifications designed to augment transdermal permeability include:

• Increasing the thennodynamic activity of the drug in the delivery system. The
simplest method is to increase drug concentration. If at saturation, other techniques

•
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Ie 1: The
cts offavorably altering partitioning (K)>>
Ii
ivity (D), drug solubility (S), and membrane thickness
(h) on lag time, time to steady-state, and steady-state flux;
(' =increase, +=decrease, O=no change)

The one variable that, when increased, favorably alters the three parameters of
lag time, time to steady state, and steady state flux is diffusivity (0);>

Therefore,

permeation enhancers which have the most profound effect on the permeation profile are

these which increase diffusivity .
III studying the effects of potential permeation enhancers on the stratum corneum,
tie m.ianismof action may be revealed by measurement of the lag time (Guy 1988) .
Purtherinsight can be obtained by considering how the partition coefficient alters in
.-june·~ n

with the diffusional lag time. If the lag time shortens in the presence of an

Mkancer, out the,.partition coefficient does not change, then the enhancer must have acted
• the

usivity alone.. On the other hand, if the partition coefficient increases due to

tie enlwmeer but the lag time remains the same, then the enhancer is affecting
~tioBiBg

intotne·skin . These deductions assume, of course, that the enhancer has no

effect Ol':;the diffusional

th length . As discussed previously, in some instances this may
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thermodynamic activity in the delivery system.
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CHAPTER IV

Transdermal Permeation Enhancement

51
4.1 Introduction
The future of transdermal delivery lies mainly in the ability to overcome its
exisfift, limitations. The main limitation is that most compounds cannot sufficiently cross

the stratum corneum barrier. Research efforts are now geared toward the development

of adjuvants which promote the transdermal permeation of ·drugs.. A comprehensive

review by this author of the U . Sm patent status in the transdermal field revealed that of
the

-patents examined, over 40% were for permeation enhancement techniques .
Permeation enhancers function by altering the barrier properties of the stratum

.ern... thereby enhancing passive permeation"
enhan~ent

The possible mechanisms of

include (Francoeur 1985):

:. alteration of the intracellular protein structure which results in increased
diffusivity ~
,

alteration of the affmity of the skin for the drug which changes the

skin/vehicle partition coefficient
• fluidization of the intercellular lipid structure which results in increased
fiiffusivity (plasticizer effect) .

• extraction of lipid components which removes the lipid barrier effect .
• ,increased skin hydration which changes the skin/vehicle partition

ooefficient and/or diffusivitYe
• osmotic shear or stress which alters drug diffusivity

&

• unspecified irreversible damage to the stratum corneum"

52
It is likely that many of these agents operate by more than one mechanism.. Table
21ists many of the permeation enhancers found in the literature (Allenby 1969, Higuchi

197i, :Breuer 1979, Smith 1979, Southwell 1983, Nagai 1983, Zupan 1984, Francoeur
1~35,

Sate> 1988, Okabe 1989, Wong 1989).

It is important to note that enhancers function strictly by altering the structure of
Ike stratum corneum and opening it up to facile diffusion. In other words, enhancers are
:lot druB carriers per se, but allow for increased mass

transport~

Many permeation enhancers within the transdermal dosage form are also good

solvents for drugs and increase flux by increasing thennodynamic activity through
mcrease4 salubility. Although not true permeation enhancement by definition, this effect
shluld De accounted for and possibly even taken advantage of..

However, the

ma4ef1llacies of a dosage formulation should not be concealed by increasing the

Hncentrawon in the dosage form, which may lead to precipitation or intensification of

at toxicity .
The selective effect of an enhancer is the result of a tridimensional interaction
ietween the drug, the skin, and the enhancer. Most dosage form excipients function to
the dosage form,.

.tipient

Enhancers alter the target tissue and is therefore an active
1t

tt
"

From a practical standpoint enhancers should meet certain requirements.. They

sieuld be systemically inert elliciting no pharmacologic effect. Their action should be

specific to the stratum corneum, affecting no other skin layers., Involvement with other
liVing .ssue'layers would result in a possible irritant or allergic response due to cellular

insult.. They should act quickly and with predictable duration.. The effect should be
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2: Agents Studied As Transdermal Permeation Enhancers.
The chemical class, a general structure, and specific example(s)
are given for each agent

Alkyimethy!sulfoxides'l
3

Jli)imethylsulf<1)xide (DMSO)

Monocarboxcyclic acid esters
CH 3 -(CH 2 ) ~Oo--R
Caproic acid ethyl ester

Phosphine oxides
R 3 p=--: 0
Dodecyi dimethyl phosphine oxide

Dicarboxcyclic acid esters
Alkylmethy lsulfones

HOOC~-(CH2}~OO--R

Unsaturated alkyl cyclic ureas
R
o

R-SG 2 CH 3
~jmethylsulfCine

1

Sebacic acid ethyl ester

JI

o---c -

(CH,J n CH

CH - A
2

amino acids

1 -methyl-4-imidazolin-2-one

Alkyl amldes

i

-3-methylenedecanoate

H 2 N-C-"-COOH
Glycine

Nt N-El}imethylacetamide

Sugar esters

N! N-mlmelhylformamide
N,N-miethyltoluamide (IDEET)

1,3-dioxanes

Sucrose mono-oleate
2-n-nonyl-1 !3 dioxane
Halogenated alcohols
X;- C -GH 2--QH
N-methyI2-pyrrolidone

Trichloroethano!

Fyrr{)!\jlutamates

Nicotinates

OCH;R
Various solvents
-- chloroform
-- ethanol
- propylene glycol
- ethyl acetate

Benzyl Nicotinate

Cyclohexanones
Cyclic manoterpines

CH 3

CR 3

2-tert-buty!cyclohexanone

Um~nene

Alkyl N, N-disubstituted amino
chain fattyacids/a!coho!s

acetates

oII
Cfi (CH 2 ) i1D-C-CH 2 NR 2

c~ (C~)n
cis~@leic acid

decyl N, N-dimethyl amino acetate

(lPM)

Ethoxylated amines

CH 3 CH2 0-NH- R
hexamethylene -Iauram ide

bis-2-hydroxyethyloleylamine

AzoneffJ)
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Jeversible, restorln.gmllbatrier .function aftertertninationof .therapy·~. Theenbancer
. should functio~inonedireCtioIloruY;i. e~ ·.·'Promotff<theoenettationof substarice:simo'tne
with no .1~$sofbOd.yfluids,.·eIectrOlytes, . :etc~ . . .• oufof the'sk:iri~ . .

·Theforn1:ulation.

sh.uld be stal>:le~·:.nori~lmtatifig;non-aIlergenlc,···andcosmeticillly··acceptable~

To .da~;·ttle()nlyma.teriat .serving .the . function 'as ··.a· transdermal·· permeation
Mhancer in a.oommercially··marketedsysfem···Ui·ethanol<irrtheiestI'adiolpatchmaiketea
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·sea····• $eries······.of.··.tnmsdermal······perlneatlOn·.·. ··.erihanCeis.·.• ··()f··.~this·ites~h.·:·•.••·W~:

The pr
~a8od

en the knQW

ge>oftheacttonoftbloglycoli.cacidon······haitaridthekriow

the effect of PQlymefcliJsSilirikirlgbnsOlure

··.a:re·used····as·.comPonents.6f··over. .the~rounter.·depilat()nesi

Thi0g1y~~lit~,.com·· ····Utlds•.

Wltea adjusted
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the same degree (Barry 1972)D

An inviolate rule of diffusion is that molecules will follow the path of least
lesistance.

In extensive studies of diffusion in polymeric matrices, the path of least

FeSistance is determined by, among other factors, the extent of cross-linking and packing
ef polymeric chains (Flynn 1985)$

The polypeptide chain of keratin is not unlike the physicochemical ultrastructure
ef synthetic polymers..

The direct dependency of solute diffusivity in polymers on

tress-linking and the action of thioglycolates on human keratin seeded the hypothesis that

tilieglycfJimes could reduce the disulfide linkages in the keratin protein diminishing the
numher of cross-links between ,polypeptide

chains~,

It is proposed that this weakens the

.ratin IJ,nd allows for increased solute diffusivity in the stratwn corneum,.
The specific reaction of thioglycolic acid \-vith disulfides, particularly cystine, the

amID€) acid in keratin protein responsible for disulfide crosslinking, is given below (Barry
1!J72). This reaction is reversible with an equilibrium constant near unity (Cleland 1964,

GelSh0n 1972)
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Figure 1'." The stoichiometric reaction between the cystine amino acid linkage in keratin
ami the primary aliphatic thiol thioglycolic acid&
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By inductive reasoning a series of low molecular weight primary aliphatic thiol
cempeunds was proposed as potential permeation enhancers.. These include metallic salts

ef thioglycolic acid, esters of thioglycolic acid, thiol alcohols, and thiol amines restricted
$0

straight chain alkanes that have at least one free sulfllydryl group on an alpha carbon .

These compounds theoretically should reduce cystine in a manner similar to thioglycolic
aci4~

4.3 Methods of Disulfide Cleavage
The cleavage of disulfide bridges is used extensively in biochemistry research

Iecause ef its importance in both functional and structural studies of proteins. The three
(N}mmeD available methods for accomplishing this cleavage are oxidation, suljitoiysis, and

reduction, each having potential in transdermal permeation enhancement. Oxidation,
.ih as with periormic acid, is simple but suffers from lack of reversibility as well as
udesirable side reactions. Sulfitolysis shows difficulty in achieving complete reaction .
1\e4uction reactions are preferred because they occur measurably fast
ale

free of side reactions (Fava 1957, Konigsberg 1972)..

«

5 minutes) and

They also proceed to

.mpleteness* (Konigsberg 1972).. Reductive disulfide bond cleavage is s:POntaneously

nWlfsible (upon exposure to atmospheric oxygen) thus satisfying probably the most

impertant criteria of a transdermal permeation enhancer .

* With proteins, the context of completeness refers to thestat.e of the native molecule~
Disulfide bridges holding together two or more polypeptide chaim are often accessible
without unfolding the polypeptide chain whereas intrachain disulfide bridge8 usually are not~
Therefore, with in situ proteins, reduction offers complete interchain disulfide breakage. For
cemplete reduction of all protein disulfide bonds, the polypeptide chain must be unfolded,
exposing all the disulfide bridges, and using excess reducing agent$ Solutions .of 8M urea
or 6M guanidine Hel are most commonly used to achieve this~ This suggests for this
research that only interchain disulfide bonds in keratin are being cleaved"
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4114 Penneation Enhancer Candidate Screening
The initial criterion, based on the hypothesized mechanism of action, is the

enhanicr must be a low molecular weight primary aliphatic thiol compound@
SplCitiwly, this requires the molecular structure to consist of a straight chain alkane

limitM to about four carbons with at least one free sultbydryl group on an alpha carbon
and a molecular weight not exceeding about 150 g/moL

Final choice of enhancer

caniites was based on availability, cost, existing toxicologic data, and physicochemical
characteristics including known reactivity and stability_The structure of each enhancer
testiG is given in Table 3..

A discussion of the known disulfide reducing

capa\lHity/hiological activity and physicochemical description of each of the chosen

enhancers is given below .

4.4.1 Blioglycolic acid ethyl ester

A very limited amount of information was found on the uses of thioglycolic acid

ethyl ester~ The methyl, ethyl, and propyl esters of thioglycolic acid have been used as
griwth pFomoters for insects, fish and other animals (Kamata 1986),.
11tBoglycolic acid ethyl ester has a molecular weight of 120& 17 g/mol and exists

as a clear · uid with a strong unpleasant odors It has a boiling point of 156-158 C and
<II

a iensityof IJi>9

many

'ti~r

g/mL It is miscible in alcohol, ether, chloroform, benzene, and

organic solvents.. Synonyms include mercaptoacetic acid ethyl ester and

ethylmer~toacetate,.
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4.

Sodium thioaIycolate
Metallic salts are used extensively in OTC depilatories and incold-wavmgof hair

(a"pmnanent~)..

As a depilatory, the sodium and calcium salts are most commonly used

in 2-4% strengths (Windholz 1976, Miller 1986)..

As a cold-waving solution, the

ammtnium sallis preferred (McCord 1946, Kolar 1972, Matsunga 1988).
Sodium:woglyoolate has a molecular wei

t of 114.11 g/mol, exists as white

hygreuopic exystals with a slight characteristic odor.. It is soluble in water and slightly

.lu1ril in alcohol. Synonyms include sodium mercaptoacetate"

4.4.3 Mercap,oethanol

The disulfide reducing reagent utilized for many years for in. vitro biochemical
pretes researcb, was mercaptoethanol, until recently, when dithiothreitol (Dm became

eemmerGially available. However, mercaptoethanol is still being used currently in some
ils~,

for example, as a disulfide bond reducer to aid in determination of enzyme

stliility and suuc,ture-acttvity relationships (Bhatnagar 1989, Kirley 1990) and in specific

iie-arKtl)1ical techniques requiring disulfide reduction (Thakur 1990) . Mercaptoethanol
iu alseicen used as a disulfide reducing agent to produce low molecular weight keratin

. om

raw keratin .{Kao 1

)..

Mercaptoethanol has been shown to be effective in

iiSSlCiatiRg the intermolecular linkages of the head and tail of sperm at the inner nuclear

. aemillDe and the nuclear chromatin junction.. The inner membrane of the nuclear
.vell,il anchored by disulfide bonds to these nuclear proteins (Young 1983) .
Il....ptootbanol has a molecular weight of 78 . 13 g/mol and exists ruraclear

6()

liClluii witb:;"a strong characteristic odor..

1143 g/m!..

density
SynonYlls

2-hytirox

include

It has a boiling point of 157-15SoC and a

It is miscible with water, alcohol, ether, and benzene .
beta-mercaptoethanol,

2-hydroxy-l-ethanethiol,

ylmercaptan, and thioglycol .

4.4.4 DiQliothreitol

Di:

reitel has now been widely adopted for biochemical protein research for

its many advantages over mercaptoethanol or other thiols..

The disulfide reducing

reaction p~Qeeeds to completion because it proceeds one step further than that seen with
tie thi

·c acid-type reaction with the fonnation of a stable six-membered ring that

it energe '"

y favored over the mixed disulfide' formed with thioglycolicacid-type

Mctiens

7 and

'~'leland

25°~)'<is

1964, Konigsberg 1972). The redox potential of dithiothreitol (at pH

-O.33V compared to -O . 22V for cysteine..

"Iuilibriunl~onstant of

it keratin,

1

This results in an overall

for the reduction of cystine, the disulfide-forming amino acid

dithiothreitol. Since the redox potential for mercaptoetlianol, dimercaprol,

'.i.,lyc01atos.,,;/and other thiols is close to that of cysteine, the

arent overall

tftuiliirium :cPnstant for the reaction is close to unity; thus a large excess of thiol is
'rtlAluire4 f0f:::"(1)mplete reduction (Cleland 1964; Konigsberg 1972) . , Dithiothreitol can
fere be ,used at much lower concentrations and is capable of quantitatively reducing

ii$Ulfides

maintaining the thiols in a reduced 'state.. Dithiothreitol is more resistant

te.air exicia'itntnan other thiols (higher stability), and has no characteristic offensive
m~ptln

Recent~::'~amples

of the use of dithiothreitol are Dewar (1989) who used

61
iithlethreitolspecifically for its disulfide reducing capability in dopamine receptor

affinity smdies and Shah (1989) who used dithiothreitol to determine the location of
tisulfiEie oonds in the enzyme diamine oxidase* Matolsty (1975) solubilized about 90%
ef epidermal keratin by using an alkaline buffer containing a reducing agent, such as

iithiothreitol, to split disulfide bonds., Like mercaptoethanol, dithiothreitol has been
••wn to be effective in dissociating the intermolecular linkages of the head and tail of
sperm at the inner nuclear membrane and the nuclear chromatin junction.. The inner

. memirane of the nuclear envelope is anchored by disulfide bonds to these nuclear

pceteins

~reung

1983).

Dithiothreitol has a molecular weight of 154,,24 g/mol and a crystalline shape of
slightly hygroscopic needles" It has a melting point of 42-43

0

C~

water, ethanol, acetone, ethyl acetate, chloroform and ethere
.i,4~i.ithi0t~reitol,

DL-threo-l,4-dimercapto-2,3-butanediol,

It is freely soluble in

Synonyms include

threo-2,3-dihydroxy

·-1,4-thiolbutane, Cleland's reagent, and DL-DTT<I

4.4.5 Cysteamine
Cysteamine has been shown to have a variety of biological effects..

It has

nwiilpretlClive capability of normal skin by protecting, transforming, and scavenging

- . radicals"'· (Verhey 1983, Held 1984)" Cysteamine also decreases acetaminophen
hepa.tetGxicityby decreasing the cytochrome P-450 dependent formation of the toxic
aClWninoph,n metabolite mercaptopurate (Miller 1986)..

Dunsford and co-workers

(1914) evaluated cysteamine as a potential inhibitor of carcinogenesis..
sUJlestid

plIssible

tissue-specific

anti-carcinogenic

properties..

The data
Cysteamine

ClntQsb1984)~· . .

·Trier and

CG-w:orirers (1987) and .; ~uiandco~wotk:ers(1987) iride.pendently indicated that

cysteamine has agasttoprotective effect on ethanolinduced:gastricIll1J:cosaldamage*

,ituitlrytissue, c

.f rei bloed cells ~dobservedincrea.sedpetn1eability~
.

.'

Elysteamine 1l(i$iamQleeularweightof:17.15·:glmol··andexists

,

MD~).

···1)l,melrcat.rOI

iiechemical rerepter bill

~gstudies(Yoshlkurti19881~
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148-C and: <a density of 1. 2385 g/mL

Synonyms include 2,3-dimercapto-l-propanol,

1,2-dithioglyrerol, British Anti-Lewisite (BAL), dicaptol, and sulfactin.

4.4.7 MOBothioglycerol

Mel1othioglycerol has been used tberapeutically in humans and by veterinarians

hi a 1:5800 strength to promote wound healing (Windholz 1974),.
MOlloiliioglycerol has a molecular weight of 108., 16 g/mol and is a yellowish
visctlus liq1Uidwith a density of 1. 295 glmL It has a slightly sulfidic odor and is soluble

in water,.:,;miscible in alcohol, and insoluble in ether..

Synonyms include

3..mercapt~l,2-propanediol, alpha-thioglycerol, thioglycerol, and thioglycerin .

4.S TraBStlllGmal Drug Candidate Screening
Although the objective of this research. is to develop a permeation enhancer

. hliependentv:0f the drug used, certain limitations dictate a systematic approach in the
<identificatitlllOf

tentia! transdermal drug candidates..

Criteria for drug screening

.' iaclu4e:

•

D"..Since percutaneous drug diffusion is a slow, concentration dependent

procests, the drug must be pharmacologically potent in order to allow its

fermulati0n in a suitable delivery system for application onto a limited surface
area.;A corresponding oral dose should not exceed the double-digit mglday
range . ,. Depending on the extent of drug absorption and first-pass hepatic

metabolism, therapeutic plasma levels provide a more accurate description of
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Figure 37(6) and (b): Transdennal flux and cumulative amount permeated profiles of
flurbiprofen through human skin in vitro after pre-treatment with enhancer as compared
to no enhancer.
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cnough to permeate skin keratin and enter the systemic circulation"

.WlQ!1n..

An obvious requirement is that no component

the tnmsdermal

I,tem should cause localized irritation or hypersensitivity.. Mild irritation may

tably minimized with proper formulation..

Transdermal dosage form

t19mponents should be tested for primary irritation early in the development stage .

•

Proteins in the skin may serve as binding sites for certain drug
molocules.. Bound drugs cannot diffuse as intended.. This also contributes to the
Jacrvorr effect.

Binding may also allow sufficient time for potential drug

.embolism by dermal enzymatic activity .

•

·

~

., Transdermal delivery is initially limited by the time of drug diffusion

time) yet once steady flux has been established, therapy can be maintained

. iadefmitely,. Therefore this route of administration is suited, and ideally so, for
cARmie conditions where continuous zero-order drug input is most efficient.,

•

The inconvenience of frequent dosing of drugs with short
pharmacologic half-lives is minimized with continuous tnmsdermal delivery.

versely, drugs with long pharmacologic half-lives are inherently long lasting

for the elimination kinetics are ca

dUN_en of effect. These
C811trolled release offe.

Ie of maintaining a (desired) prolonged

of compounds may not benefit substantially from
by tnmsdermal administration .
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These criteria constituted the basis of choosing transdermal drug candidates from
the standpoint of a clinically useful, marketable product~ It is important to note that the

m04el drugs for this research were chosen initially for specific experimental reasons,
then their clinical applicability and feasibility was evaluated.. A discussion of each drug

utilized in relation to their experimental value and qualification in meeting the above
criteria is given below" All information was obtained from ~~~~~~~~

lCastrup, Ed., I.B. Lippincott Co . , SL Louis, MO., except for aqueous solubilities and

oil/water partition coefficients which were

experimentallydetermined~

4.5.1 Acetaminopnen
Acetaminophen was chosen as a model drug because it possesses an adequate
Mlance between hydrophilicity (aqueous solubility of 14 mg/ml) and lipophilicity
~il/water

partition coefficient of 3). This balance should provide some natural

pmneation from which to establish a baseline for enhancement.
Acetaminophen is a prostaglandin synthesis inhibitor (pGSI) type analgesic and
••-pyretic.,

Several factors connote transdermal delivery.

Acetaminophen has a

Jiarmacelelic half-life of 1-3 hours and a dosing frequency of every 4-6 haursm It can

,e, used to treat chronic conditions of pain andlor fever..

Oral absorption is variable

retJUiring fItS to 2 hours to achieve peak blood levels.. Acetaminophen is extensively
h~patically

metabolized (94 %) but not extensively protein bound" Acetaminophen bas

amelecular weight of 151 . 16 g/mol. The only factor prohibitive to transdermal delivery
is*e rCNIuin~d systemic therapeutic blood level of 5-20 m,gIL . This, is beyond the range

achievaile with current transdermal technology.
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4.5.2 Flul'b:iprofen

Fluroiprofen is a lipophilic compound whose transdermal route should be via the
Upephilicpathway.. If the thiol enhancers break the disulfide bonds of the keratinaceous

kydrephilic;:>patbway, then it can be hypothesized that enhancement for lipophilic drugs,
is

a class, should be minimal to none.. Flurbiprofen was chosen to test this logic .
Flurl>iprofen is a Non-Steroidal Anti-Inflammatory Drug (NSAID) whose activity

nes 1

I)' upon prostaglandin synthesis inhibition.. Most NSAIDs are used for their

a-inflammatory effects in treating chronic arthritic conditions but effective analgesic

••vity renier them useful for mild to moderate pain as well.. Flurbiprofen is a viable
tIUlsaermaldrug candidate in terms of its pharmacologic half-life
ftlquency ofd:osing (up to 4 times a day) but its daily required oral

(for rim,tis) would be difficult to deliver transdermally"

(5~7

hours) and

dosage of 200-300

However, Mceall

lSABs un.dergo extensive hepatic metabolism, avoidance of the "first pass effect·· with

tallsdermal delivery may lessen this limitation to within the realm of transdermal
viUility.. Additionally, a lower dosage for indications such as pain, dysmenorrhea, and

s.ium may be feasible transdermally . Flurbiprofen, like other NSAIDs taken orally,

can .use serious gastrointestinal

toxicity such as bleeding, ulceration and perforation .

can occur at any time and without warning and have resulted in hospitalizations

ani even

fatal·ities~

This negatively impacts the use of the oral route.. Molecular size

wald net preClude transdermal delivery (244,,27 g/mol) but its lipophilicity may, for

fl.iprofen has an aqueous solubility of 0.034 mg/ml and an oil/water partition
lcient of.. Also, all NSAIDs are highly protein bound (> 90%) which presage
.. 1"'!.....
MUR

proteIn b"··m··d"Ing.
3
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mterestingly, flurbiprofen is marketed in a transdermal system in Japan by Mikasa
Pharmaeeu,uca1s (pfister 1990)

a

4.5.3 Beuoic acid
Beuwic acid was chosen as a model compound because is has been studied

extensively by other researchers because of its relatively high natural skin permeation
rate (Scheuplein 1974, Guy 1982, 1984, 1985, Cooper 1984, Bronaugh 1986, Dupuis
1936, :Bemer 1988, Parry 1

). The results of these researchers can thus be used

.mparaiiv:ely to validate this research. A second reason is to elucidate the effect of the
.ial enhaneefs on the permeation rate of a compound that naturally exhibits a relatively
!Blh permeation rate" It also bas the advantage of being stable and an excellent U" V .
~semer.

nzoic acid has a molecular weight of 122.12 glmol, an aqueous solubility

.. 3~5 ms/ml and an oil/water partition coefficient of 0 . 114_
Beuoic acid has no therapeutic activity as a drug per se but is used

as

a

preservative in pharmaceutical preparations.

4.5.4 Xau • e series

A homologous series of xanthine compounds, most of which are drugs that would
aefit frem transdermal delivery, were chosen for study in terms of changing

Ii

hilicity.. The compounds in order of decreasing aqueous solubility are: dyphylline,

caJltJl*n,e, theophylline, and theobromine., This series of compounds was studied with one
'f tie mer, promising enhancers--thioglycolic acid ethyl ester,. Xanthine derivatives,as
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at class, have activity as diuretics, smooth muscle relaxants, cardiac stim

ts, and

vasodilatnrs.

4.5.4.1 TIl

ylline
phylline is ,a xanthine derivative indicated for the chronic treatment of

iDn»nchiaf"a,s,thma..

The main characteristic of this drug that advocates transdermal

delivery isnits narrow therapeutic index. Therapeutic serum levels range from 10. .20
jig/ml with dramatic increases in toxicity seen with levels of 20-25 Itglml. Adverse

reactions seen in more than 75 % of the patients include nausea, vomiting, diarrhea,
, ieadache, insomnia, and irritability.. Toxicity becomes life threatening at levels above
",g/ml

th cardiac arrhythmias, seizures, brain damage, and death..

presence o:j:·food and food type

Since the

rein/carbohydrate ratio) alters the bioavailabilityand

aisorption pattern, controlled transdermal delivery is highly advantageous. Other factors

also suppol1t"transdermal delivery.. Oral theophylline causes local g. i. irritation and
.Ulually re€lulres administration with food.. Theophylline is extensively biotransformed
il the liver;

95 %).. Serum half. .life is variable from 3-13 hours in normal subjects .

uency '(Jf.,dosing varies and must be individualized for each patient.

Generally

an: every 6 hours is required.
J

Thylline has a molecular weight of lS(t 17 g/mol,an aquooussolubility of

5.\1 mg/mlandan oil/water partition coefficient of 0 . 571..

The limiting factor of

d"'vering theophylline transdermally is achieving a serum level of 10-20 Ilg/ml.
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4.5.4.2 Dypbylline
Dyphylline is a xanthine derivative whose potency is about 1/10 that of
theophylline. Its advantage over theophylline is fewer side effects.. Its pharmacologic
half-life is two hours thereby requiring frequent dosing but its therapeutic concentration
is similar to theophylline (12 jlg/ml) thereby limiting its transdermal viability.,
Dyphylline is not metabolized but excreted unchanged in the urine . Its short half-life and
lack of metabolism is due to its relatively high aqueous solubility (120 mg/ml)"
Dyphylline has a molecular weight of 254.25 g/mol and an oil/water partition coefficient
of 0.111.

4.5.4.3 Caffeine
Caffeine is a xanthine derivative used for its CNS stimulant activity" Including
its use in beverages, this is the most consumed drug in today's society..

Self

administration inevitably results in "peak: and valley" effects of nervousness,

hyperexcitement, anxiety, tachycardia, and diuresis at serum peaks and lethargy, fatigue,

and mental dullness at serum Valleys.. Caffeine has the capacity to produce withdrawal
symptoms upon cessation of regular consumption.

Controlled zero-order drug input

available with transdermal delivery would minimize or eliminate these effects.. Caffeine

has a molecular weight of 194 . 19 g/mol, an aqueous solubility of 19 mg/ml, and
oil/water partition coefficient of 0.034" It exhipits low protein binding (15 %) and a short
pharmacologic half-life (3.5 hours)..

The limiting factor in delivering caffeine

transdennally is achieving the required serum levels of 6-13 pg/ml .
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4.5.4.4

eobromine

Theobromine is a xanthine derivative which has activity as a diuretic, smooth

muscle relaxant, cardiac stimulant, and vasodilator, albeit less than the other xanthines .
It has a molecular weight of 180.17 g/mol, an aqueous solubility of 0.435 mg/ml and an

eil/water partition coefficient of 0 . 128.. It currently is not used in a marketed drug

product but is used here to complete the xanthine series under study .

,
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OBJECTIVES

The aDjectives of this study are:
1)

To establish a system for the in vitro evaluation of transdermal drug J)errneation .

2)

To screen model drugs based on specific experimental criteria.

3)

To characterize the transdermal kinetic and physicochemical parameters of model

drugs.
4)

To screen thiol compounds as permeation enhancers based on specific criteria .

5)

To determine if certain thiol compounds can be pharmaceutically used as
transdermal permeation enhancers .

')

To assess the in vivo acute primary toxicity of certain thiol permeation enhancers.

5.1 mtroduction
A diagram of the research plan is given in Figure 11. The plan was initiated by

. .blishing and testing the in vitro assay system.. Drug/enhancer compatibility and

lIt1ractions were evaluated to determine enhancer application method.

The chosen

1m,s' transdermal pharmacokinetic and physicochemical permeation parameters were

6letermined with and without enhancer. Permeability coefficients were compared for

.listical differences.. Finally, animal and human primary skin irritation effects of the
eaiancers were assimilated.. This information was then collectively used to critically
enluate the use of primary aliphatic thiols as transdermal permeation enhancers .
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5.2 Materials and Methods
5.2.1 List of Materials
5.2,,1,,1 Chemicals
Acetaminophen, Ruger Chemical Co, Irvington, NY, Lot # G18804C18.
Acetic Acid, Glacial, Fisher Scientific, Fair Lawn, NJ, Lot #896949; Lab Grade.
Ammonium Acetate, Fisher Scientific, Fair Lawn, NJ, Lot #289756; Lab Grade"

Ienz0ic Acid, Sigma, St. Louis, MO, Lot # 78F-0390; Cat. no. B-3250; Lab Grade,

Caffeine, Sigma, St. Louis, MO, Lot # 127F-0395; Cat. no . C-0750; Lab Grade.
2,3-Dimercaptopropanol, Sigma, St. Louis, MO, Lot # 40H0803, Lab Grade"
BL-Dithiothreitol, Sigma, S1. Louis, MO, Lot # 117F-0032, Lab Gradee
BL-Dithiothreitol, Sigma, SL Louis, MO, Lot # 69FOO83, Lab Gradee

:lyphylline, Sigma, St. Louis, MO, Lot # 126F-0308; Cat.

nOM

D-0633; Lab Grade.

1,2-Ethanedithiol, Sigma, S1. Louis, MO, Lot # 110f-0001; Lab Grade .
:l!thyl Alcohol, Warner-Graham Co"' Cockeysville,

MD~ ,Lot

# June 20, 89; Lab Grade .

Flurliprofen, (U-27 , 182), Upjohn Co . , Kalamazoo, MI, Lot # 0498F; Lab Grade.
Methanol, Fisher Scientific, Fair Lawn, NJ, Lot #772367, HPLC grade.

Mercaptoethanol, Pierce Chemical Company, Rockford, II, Lot # 862 16084, Lab Grade .
Mercaptoethanol, Sigma, St. Louis, MO, Lot # 48F-0028; Lab Grade.
2-Mercaptoethylamine, Sigma, S1. Louis, MO, Lot # 67F-0032, Lab Grade .
Mlnothioglycerol, Sigma, St. Louis, MO, Lot # 47F-0755; Lab Grade .
Light Mineral, U . S . P., Lubinol~, Purepac, Elizabeth, NJ, Lot # C24A

SMium Chloride, Fisher Scientific, Fair Lawn, NJ, Lot #714068; Lab Grade"
SMium Phosphate, Dibasic, Heptahydrate, FisherBiotech, Fair Lawn, NJ, Lot # 885404;
Cat. no. BP331-500; Enzyme Grade .

#

no.

#
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Lotus Development Corporation, Cambridge, MA

Jer Text, Figures, Tables, And Equations:
WORDPERFECT (Version 5.1)
Wordperfect Corporation, Orem, UT

Por Graphs:
SLIDEWRITE PLUS (Version 3)
Advanced Graphics Software Inc . , Sunnyvale, CA

Per Chemical Structures:
MOLECULAR PRESENTATION GRAPHICS
Hawk Scientific Systems, Inc., Kinnelon, NJ
Fer l)ata Manipulation And Analysis:
LOTUS 1-2-3 (Release 2.01)
:lotus Development Corporation, Cambridge, MA

5.2.1.4 Equipment
Spectrophotometer:
Variable wavelength U . V . spectrophotometer . Model 481 (pn98293)
Millipore Corporation, Waters Chromatography Co . , Millford, MS
Fixed wavelength U . VI) spectrophotometer. Model 441
Millipore Corporation, Waters Chromatography Co . , Millford, MS
U"V. Diode Array Spectrophotometer. Model 5451A
Hewlett Packard Company, Cupertino, CA .

Integrator:
Control module. Model 740
Micromeritics Instrument Corp . , Norcross, GA
Chromatopac· Model C-R3A
Shimadzu Corp . , Kyoto, Japan
Recorder:
Single channel strip chart recorder .
Linear Instruments Corp . , Reno, NY
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Chw;ulat0r:
Constant temperature water bath. Model 800. Catalog no . 13-874-71A .
Fisher Scientific, Fair Lawn, NJ

Di

lion cell:
Franz flow-through model FDC-200, 9mm.
Crown Glass Co . , Somerville, NJ

Fluid delivery systems:
Volumetric Infusion Pump. Micro 965 CA92131 (pediatric).
lMED Corporation, San Diego, CA
HPLC Pump. Model 750
Micromeritics Instrument Corp . , Norcross, GA
Sample Injector. Model 7125 equipped with a 20J-Ll injection loop
Rhoodyne, Cotati, CA
HPhC column:

Reverse-phasee

Microsorb~

CI8, 5JLm particle size

Rainin Instrument Co. ,Emryville, CA

5.2.1.5 Supplies
Filters:

Millex-SV, 0 . 5 p'm pore size,
Millipore Corp., Bedford, MA

Patties:
Hill Top Research, Inc . , Cincinnati, OR

5.2.1.5 ADimals
Guinea pigs:
Athymic male nude (hairless) guinea pigs
Charles River Co . , Willimington, MA
Plumas:

Normal male and female caucasians, Charleston, SC
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5.2.2 In Vitro Assay
The following discussions describe not only the components and procedures of the

in vitro assay system but also describe the rationale for each .

S.2.2.1 Selection and Rationale for Diffusion Cell Design
The system is designed as a continuous flow-through type as opposed to a finite

sampling system in an effort to automate and expedite the evaluation process.
Continuous sampling allows continuous monitoring of the permeation profile which

allows the visualization and elimination of extraneous interferences such as electronic

spikes, air bubble spikes, and the like.. Sink conditions are easi.ry maintaiIled
IOntmuous flow-through systems even with studies that accumulate large amounts of

.lute (Bronaugh 1985).. Flow-through more closely mimics blood flow through the skin
taking 'up and carrying away permeating compounds.. Also better mixing is obtained

with the flow-through cell.. In a study of the permeation of a homologous series of
p-aminebenzoates, as the series is ascended, there is a shift in diffusion controlled by the

aembraneto one in which permeation is controlled by the aqueous diffusion layers.. It

was apparent that the effective thickness of the aqueous boundary layer is less when the
flew-through cell is used thereby returning control of diffusion back to the membrane
fA,ddicks 1987). Flow-through cells are recommended in the FDA and AAPS Guidelines

fer they tend to minimize collection problems (Skelly 1987) .
In a'.diffusion cell system, the total quantity of solute that can accumulate in the
rlteptor compartment is determined by its affmity for the receptor fluid (solubility) and
the volume of the receptor compartment. Together, this affInity and volume define the
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Witlding capacity" of the receptor compartment (Riley 1985).. In a static system, the
IlCeptefvolume is fiXed.. Therefore, the holding capacity can be increased only by

eian:ing:,the relative affinity of the penetrant for the receptor fluid, which leads to

deviations from in vivo mimicking.. However, in a flow-through system, the receptor
velume becomes infinity large as flow rate is increased.. The holding capacity can be
ilcreased,indefinitely by increasing the flow rate.

J.2.2.2Seurce and Rationale

r Membrane Selection

Many in Vitro experiments are done with animal tissue. This is usually done out
necessity rather than preference because the procurement of the appropriate viable
h,.an tissue may be difficult or impossible..

a Ii••on is on

Ideally, a product whose ultimate

human tissue dictates that testing and development should be on that

Additionally, extrapolation of animal data to human biological systems is

inherently error laden.. This is pertinently evident with transdermal permeation studies

wtLere permeation differences between human and animal skin of 0 . 5 to 40 fold have
observed depending on the drug used (Bronaugh 1982, Scott 1986).. Montagna
(1974) pointed out that no animal skin sufficiently resembles human skin to serve as a

leural model for transdermal studies . In general, animal skins are more permeable than
hUlUn skin (Bond 1988, Friend 1989) . For these reasons the use of human epidermis

is ,referred., All in vitro experiments of this study are done with human tissue. Since
the rate limiting barrier, the stratum corneum, consists of anucleated, metabolically

.active oomeocytes, in vitro data has been shown to correlate well with in vivo
permeation profiles (ldson 1975, Franz 1975, 1978, Bronaugh (I) 1982).
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The skin must be fresh, healthy, disease-free and undamag
stratum corneum..

,especially the

Potential sources are from cadavers or from cosmetic surgical

procedures. Epidermis from cadavers may have a questionable history

death to receiving the tissue; the most common variable being the length

time of
SInce

death. In contrast, epidermis from plastic surgery can be obtained immediately after

removal and utilized promptly or frozen, thereby assuring minimal cellular decay. One
cosmetic surgery procedure that provides a sufficient quantity of epidermis is reduction

mammoplasty

B

All skin used in this study was obtained from this source.. The source

of skin is controlled with respect to anatomical site, sex, and race but not age, although
the age was noted for each sample and limited to a maximum age of 50 years. Use of

epidermis from one anatomical site minimizes the intra-specimen variation in
permeability (Kermici 1977, Southwell 1984).

The FDA and AAPS Guidelines

recommend specifying the source of the skin: whether from a surgical procedure or
excised (from cadaver) (Skelly 1987).
Another potentially important variable minimized by use of breast epidermis

the effect of environmental exposure on permeability" The most poignant environmental

factor is ultra-violet radiation (UVR) (sun exposure) which normally is dismissable with
'breast tissue.

5.2.2.3 Receptor Medium
The diffusant receptor medium is designed to mimic physiologic conditions. It

consists of a sterile, pH 7 . 4 phosphate buffered isotonic saline solution (Sorensen
phosphate buffer)a A 0 . 001

concentration of phenylmercuric acetate (Hadgraft 1986)
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or a.OO5% thimerosal (Katz 1971, Bronaugh 1982) is added as a preservative .
Thimerosal is preferred due to a higher aqueous solubility.. The formula used is given
ielow .

Monobasic Sodium Phosphate monohydrate (Fisher) ....... ,. ........... "" ... "." 3 . 68 grams
Dibasic Sodium Phosphate heptahydrate (Fisher) ............................. ". ".". 28 . 58 grams
Sodium Chloride (Fisher) ............. &" ..........
8 . 80 grams
Thimerosal (Sigma) ............. "' ........................................ '" .... "" . "......................................... ".... 0 . 10 grams
Sterile Water (Travenol) . "'"" ........................................................................... "................................q . s.
to make .... "' ........ "" ........................... ., ...................................................................................... ". ".......... 2{)()() ml
s .... " . . . . . . . . . " .. " .. " . . . ,." . . . . . . . . . . . . . . . . . . . . . " .... ,. .. " .. "

The solution is filtered (Millex-SV) and sonic-suctioned degassed prior to use .
A four week expiration date is arbitrarily assigned .

5.2.2.4 Transdennal Diffusion Cell Operation
The diffusion cell is a two-chambered jacketed Franz diffusion cell (Crown Glass
Co. ). The cell and related components are made of inert, nonreactive materials .

incl\ldes all accessories such as tubing, collection chambers, etc.. This is consistent with
the FDA and AAPS Guidelines (Skelly 1987).. Figure 12 shows a schematic illustration

of the diffusion cell with related support equipment..

The diffusion membrane was

sandwiched between the donor and receptor half-cells..

The receptor half-cell is

,lass-jacketed and was maintained at 37·C via continuous circulation of water from a

constant temperature water bath (Fisher).. A magnetic stirring bar was operated in the
tor half-cell to minimize the hydrodynamic diffusion layer of drug underneath the
membrane. Stirring rate was constant for all experiments.. The donor half-cell is not
jacketed therefore the drug formulation was at room temperature except for residual heat
transferred from direct contact with the membrane.. This is consistent with in vivo
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skin in vitro with no enhancer, ethanol, and mercaptoethanol. (The
. error bars are the standard deviation/or n=3.)

repared and analyzed by HPLC according to the following chromatographic conditions:
'; The mobile phase was prepared by mixing 2.0% by volume 1M acetic acid

(Fisher), 7.5% by volume 1M ammonium acetate (Fisher), and 4.9% by volume HPLC

e methanol (Fisher), with 85.6% by volume distilled water. The procedure utilized
Mic~ meritics model 740 control module, a Micromeritics model 750 solvent delivery

system, a Rheodyne model 7125 injector equipped with a 20 JLl injection loop, a 5JLm

'nin Microsorb~ C l8 reverse-phase column, a Waters model 441 UV detector, and a
"

matopac~ model C-R3A integrator (Shimadzu). A 20 JLl sample was injected on the
(

lumn with a constant flow rate of 1.0 mllmin. The absorption was monitored at a

"

wavele!lgth of 254 nm.
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fly accommodated by the lipid phase (e.g. steric hindrance), will display low skin

rmea.tion despite predictions to the contrary (Michaels 1975).
The use of mineral oil as a correlation parameter to stratum corneum partitioning

has distinct advantages. When direct determinations are made using pieces of stratum
corneum, the partition coefficient is complicated by several considerations. For drugs
that are highly protein bound, it is impossible to tell to what extent partitioning is due
t binding instead of solubility. This is indistinguishable even with analytical methods

that directly measure each phase independently (such as scintillation counting). Bound

m lecules do not contribute to permeation. A second problem is that experimentation
involves soaking the stratum corneum for extended periods of time resulting in full
hydration and extensive swelling eventually resulting in tissue maceration.

This is

inconsistent with in vivo conditions. Southwell et al (1983) measured the actual stratum
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Figure 33: The 95 % Least Significant Difference (LSD) intervals for the permeability
coefficient means of transdermal benzoic acid.
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7.3.2.10 Discussion
As originally stated in the experimental design, the purpose of studying benzoic
acid is for comparison with the extensive work of other researchers thus serving to
validate this research. A detailed study was recently published by Parry (1990) and most
closely correlates with the parameters of this work.

A direct comparison of the

parameters and results of Parry's work and this work is given in Table 23. The critical
parameter for comparison is the permeability coefficient. Parry's system resulted in a
permeability coefficient of 0.031

± S.D.

0.060- cm/hr as compared to 0.013

± S.D.

0.0011 cm/hr for this work. This is adequately equivalent considering the differences
in the two systems. The most influential difference is most likely the donor solution

solute concentration since, according to Fick's law, solute concentration directly
determines permeation rate. Parry's concentration of 5 mg/ml (due to higher donor
chamber temperature) should result, as is shown, in a higher permeation rate as
compared to the concentration of 3.5 mg/rnl of this work.
The second reason for studying benzoic acid was to elucidate the effect of the
thiol enhancers on the permeation rate of a compound that naturally exhibits a relatively
high permeation rate. Figure 32 shows the changes in permeability coefficients through
human skin in vitro due to pre-treatment with various thiol enhancers as compared to no
enhancer.
Increases in permeation were seen with all of the thiol enhancers but profound
increases were not evident.

The average permeation enhancement for all of the

enhancers was 1.7 fold. The greatest effect was by sodium thioglycolate with a 21h fold
-This relatively large standard deviation is due to its calculation with propagation...of-errors.
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Table 23: Comparison of the parameters and results of transdermal benzoic acid ofpublished
data (Parry 1990) vs. this data.

Skin

Diffusion Cell

Analytical

Methodology

Experimental

Results

Skin Type

Human Female

Human Female

Skin Source

Abdominoplasty

Mammoplasty

Skin Storage

4·C (Refrig.)

-4 • C (Frozen)

Storage Solution

Tissue Culture
Medium

Normal Saline

Skin Preparation

Split-thickness

Split-thickness

Cell Type

Side-by-side

Franz

Donor Solution

Aqueous Saturated
SoIn. Supernatant

Aqueous Saturated
Solution with Excess

Donor Soln Temperature

3S·C

Room Temperature

Donor Solution
Solute Concentration

5 mg/ml

3.5 mg/ml

Donor Solution Volume

3m1

Sml

Receptor Solution

Distilled Water

Isotonic pH 7.4 Buffer

Receptor Soln Temp.

3S·C

37·C

Receptor Solution Volume

3ml

3ml

Surface Area

0.785 cm2

4.52 em2

Cell Sensitivity

0.26 em2/ml

1.5 cm2/ml

Method

Scintillation Counting

Ultraviolet

Sampling

Finite (100 1'1 q 4 hrs
with replacement)

Continuous
Flow-Through

Skin Thickness

31 #Lm

21.5 I'm

Partition Coefficient

Human SkinlWater

Mineral OilIWater

Partition Coefficient

0.114

Diffusion Coefficient

4.8
2.1 x 100s em2/hr

Permeability Coefficient

0.031 emlhr

2.5 x

l(T3

em2/hr

0.013 cm/hr
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increase in permeation.

Does this mean that for a compound with a natural high

permeation rate, large increases in permeation may not be possible? Theophylline, a
drug studied in this work, coincidently has a relatively similar aqueous solubility and
oil/water partition coefficient to benzoic acid yet a non-enhanced steady-state flux of
30-40 times less.

If this high permeation rate of benzoic acid has an effect on the

efficacy of the thiol enhancers, then the extent of enhancement between theophylline and
benzoic acid will demonstrate these differences i.e. theophylline should show a much
higher degree of enhancement than benzoic acid. As will be shown later, the magnitude
of enhancement of theophylline was similar to benzoic acid thus suggesting the extent of
enhancement by the thiol enhancer studied is due to the inherent physicochemical
attributes of benzoic acid and not on its flux capacity.
One-way analysis of variance shows that the variance between enhancer groups
is greater, due to at least one enhancer group, than the variance within each group.
Multiple range analysis using 95 % LSD intervals shows no difference between
dimercaprol and cysteamine, no difference between cysteamine, mercaptoethanol, and
thioglycolic acid ethyl ester, and no difference between mercaptoethanol, thioglycolic
acid ethyl ester, and monothioglycerol.

Otherwise, all other groups were

non-homogeneous. Cochran's test for homogeneity of variance shows non-homogeneity
of experimental error within groups.
Thioglycolic acid ethyl ester, mercaptoethanol, and cysteamine reduced the
diffusional lag time by 50% to 75%. Sodium thioglycolate increased the lag time by
three fold. The cause of this phenomena is unknown at present, but the fact that the
average lag time also increased using this enhancer with acetaminophen while no other
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enhancer did, implies that this may be a characteristic peculiar to sodium thioglycolate.
No significant reductions in lag time were seen with the remaining enhancers.

As

previously discussed, experimental error may obscure true differences.
The thiol enhancers generally caused a delay in the time to reach steady-state with
benzoic acid as compared to no enhancer.
increase was 1.8

± S.D.

1.9 hours.

The effect varied widely. The average

This delay may simply be due to the higher

steady-state flux seen with the enhancers because the rate at which the steady-state is
achieved appears to be similar to that of no enhancer. This implies no real change in
solute diffusivity in the membrane.
The results from this study suggest that for a drug molecule similar to benzoic
acid with respect to physicochemical attributes i.e. aqueous solubility of 3.5 mglml and
oil/water partition coefficient of 0.1, profound increases in permeation may not be
possible using one of the thiol enhancers.
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7.3.3 Model drug: Flurbiprofen
7.3.3.1 Flurbiprofen with Thioglycolic Acid Ethyl F&ter

TABLE 24: The effect of thioglycolic acid ethyl ester on the pharmacoldnetic and
physicochemical parameters of transdermal flurbiprofen.
The values in brackets are the standard deviations.

Diffusional Lag Time
(hours)

1.200
[0.200]

0.367
[0.153]

Time to Steady-State
(hours)

3.833
[0.153]

1.167
[0.289]

Steady-State Flux
(JLg/cml/hr)

18.32
[0.91]

18.96
[0.93]

Permeability Coefficient (P)
(cmlhr X 10-1)

5.37
[0.266]

5.56
[0.271]

Enhancement Ratio

1.035
[0.051]

(P{FManccr}/P{No FManccr})

Cumulative Amount Permeated
(p,g/cm2/day)

243.40
[19.31]

262.74
[28.03]

Approximately 1.2 hours was required for flurbiprofen to diffuse through the skin
without enhancer. The flux gradually increased reaching steady-state at almost four
hours and averaging a zero-order drug input rate of 18.32 Ilg/cm2/hr. Using Fick's law
(Eq. 20) and the the oil/water partition coefficient, an average apparent diffusivity of

1.31 x 1<r' cm2/hr was calculated. The average steady-state flux of 18.32 p.g/cm2/hr
results in an average permeability coefficient of 5.37 x 10-1 em/hr. The cumulative
amount permeated in 24 hours was an average of 243 Ilg/cnr.
Pre-treatment of the skin with pure thioglycolic acid ethyl ester had no effect on
the permeability coefficient of flurbiprofen. The average steady-state flux and cumulative
amount permeated at the end of 24 hours were correspondingly unaffected. However,
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the average lag time and the time to steady-state were significantly reduced by 70%.

This in itself may have therapeutic benefit. These results are represented graphically in
Figure

34(a)

and

(b).
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Figure 34(a) and (b): Transdermal flux and cumulative amount permeated profiles of
flurbiprofen through human skin in vitro after pre-treatment with enhancer as compared
to no enhancer.
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7.3.3.2 Flurbiprofen with Sodium ThiogJycolate

TABLE 25: The effect of sodium thioglycolate on the pharmacoldnetic and
physicochemical parameters of transdermal flurbiprofen.
The values in brackets are the standard deviations.

Diffusional Lag Time
(hours)

1.200
[0.200]

1.200
[0.200]

Time to Steady-State
(hours)

3.S33
[0.153]

7.867
[0.153]

Steady-State Flux
(JLg/cm2/hr)

18.32
[0.91]

18.56
[1.0S]

Permeability Coefficient (P)
(cmlhr X 10-1)

5.37
[0.266]

5.44
[0.318]
1.013
[0.059]

Enhancement Ratio
(p{BDbaacer}/P (No BDbaacer})
Cumulative Amount Permeated
(p.g/cm2/day)

218.99
[25.45]

243.40
[19.31]

Sodium thioglycolate had no effect on the permeability coefficient of flurbiprofen.
The average lag time was also unchanged. The average time to steady-state took about
twice as long. The average steady-state flux and cumulative amount permeated at the end
of 24 hours were correspondingly unchanged.

From these results it is evident that

sodium thioglycolate is ineffective as a permeation enhancer for flurbiprofen using this
technique. These results are represented graphically in Figure

35(a)

and

(b).
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Figure 35(a) and (b): Transdermal flUX and cumulative amount permeated profiles of
flurbiprofen through human skin in vitro after pre-treatment with enhancer as compared
to no enhancer.
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7.3.3.3 Flurbiprofen with Dithiothreitol

TABLE 26: The effect of dithiothreitol on the phiJ177U2Cokinetic and physicochemical

parameters of trarudermal flurbiprofen.
The values in brackets are the standard deviations.

Diffusional Lag Time
(hours)

1.200
[0.200]

0.767
[0.153]

Time to Steady-S~te
(hours)

3.833
[0.153]

4.033
[0.513]

Steady-State Flux
Vtg/cm2/hr)

18.32
[0.91]

41.51
[2.05]

Permeability Coefficient (P)
(cmlhr X 10-1)

5.37
[0.266]

12.2
[0.600]

Enhancement Ratio

2.266
[0.112]

(P{Fnbancer}/P{No EDbIocer})

Cumulative Amount Permeated
Vtg/cm2/day)

243.40
[19.31]

507.97
[52.70]

Dithiothreitol more than doubled the permeability coefficient of acetaminophen
(ER=2.266). The average lag time was reduced by about one-third. The average time

to steady-state was not significantly affected.

The average steady-state flux and

cumulative amount permeated at the end of 24 hours were correspondingly increased by
over two fold. These results show that pre-treatment of the skin with dithiothreitol can
double the permeability of the skin to flurbiprofen.
graphically in Figure 36(a) and

(b).

These results are represented
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Figure 36(a) and (b): Transdermal flux and cumulative amount permeated profiles of
flurbiprofen through human skin in vitro after pre-treatment with enhancer as compared
to no enhancer.
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7.3.3.4 F1urbiprofen with Dimercaprol
TABLE 27: The effect of dimercaprol on the pharmacokinetic and physicochemical

parameters of transdermal flurbiprofen.
The values in brackets are the standard deviations.

IIm~f!!i&l~lm~.¢I~I!gQl.II;'
Diffusional lag Time
(hours)

1.200
[0.200]

0.233
[0.029]

Time to Steady-State
(hours)

3.833
[0.153]

4.100
[0.458]

Steady-State Flux

(p.g/cm2/hr)

18.32
[0.91]

15.79
[0.84]

Permeability Coefficient (P)
(cmlbr X 10-1)

5.37
[0.266]

4.63
[0.247]

Enhancement Ratio

0.862

(p{Enbanc«}/P{No Fnbaoca})

[0.050]

Cumulative Amount Permeated
(p.g/cm2/day)

243.40
[19.31]

228.60
[26.03]

Pre-treatment of the skin with dimercaprol had a slight negative impact on the
permeability coefficient of flurbiprofen. However, the average lag time was significantly
reduced by 80%. The average time to steady-state increased, but not significantly. The
average steady-state flux and cumulative amount permeated were slightly negatively
affected. Reason(s) for these occurrences were not readily apparent. These results are
represented graphically in Figure 37(a) and

(b).
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Figure 37(a) and (b): Transdermal flUX and cumulative amount permeated profiles of
flurbiprofen through human skin in vitro after pre-treatment with enhancer as compared
to no enhancer.
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7.3.3.5 Flurbiprofen with Cysteamine

TABLE 28: The effect of cysteamine on the phannacoldnetic and physicochemical
parameters of transdermal flurbiprofen.
The values in brackets are the standard deviations.

1111111~'~lllllillll~!~III~~~1
Diffusional Lag Time
(hours)

1.200
[0.200]

0.500
[0.300]

Time to Steady-State
(hours)

3.833
[0.153]

3.967
[0.950]

Steady-State Flux
(pg/cm2/hr)

18.32
[0.91]

29.63
[1.46]

Permeability Coefficient (P)
(cm/hr X 10-1)

5.37
[0.266]

8.68
1.618
[0.080]

Enhancement Ratio
(p{FnhIDccr}/P{No &hanc«})

Cumulative Amount Permeated
(p.g/cm2/day)

[0.428]

243.40
[19.31]

437.01
[29.41]

The permeability coefficient of flurbiprofen increased by over sixty percent due
to cysteamine (ER=1.618). The average time to steady-state was not significantly
affected but the average lag time was reduced by 75 %. There was a corresponding sixty
percent increase in the average steady-state flux and cumulative amount permeated at the
end of 24 hours. These results are represented graphically in Figure 38(a) and

(b).
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Figure

38(a)

and

(6):

Transdennal flux and cumulative amount penneated profiles of

flurbiprofen through human skin in vitro after pre-treatment with enhancer as compared
to no enhancer.
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7.3.3.6 F1urbiprofen with Monothioglycerol

TABLE 29: The effect ofmonothioglycerol on the phannacoldnetic and physicochemical
parameters of transdennal flurbiprofen.
The values in brackets are the standard deviations.

1:!~~~l~il~~_Ii~tl[~.t.11
Diffusional Lag Time
(hours)
Time to Steady-State
(hours)
Steady-State Flux
~g/cm2/hr)

Permeability Coefficient (P)
(cmlhr X 10-1)

1.200

1.000

[0.200]

[0.200]

3.833

8.067
[0.551]

[0.153]
18.32
[0.91]
5.37

[0.266]

Enhancement Ratio

~g/cm2/day)

[1.58]
5.54
[0.339]

1.033
[0.063]

(p(FnIwv:er}/P{No Fnhmccr})

Cumulative Amount Permeated

18.92

243.40
[19.31]

192.94
[60.96]

Monothioglycerol had no significant effect on the average permeability coefficient
of flurbiprofen. The average lag time was reduced, but not significantly. Steady-state

was slowly reached, taking twice as long as the non-enhanced control. The average
steady-state flux and cumulative amount permeated at the end of 24 hours were likewise
unaffected. These results are represented graphically in Figure 39(a) and

(b).
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Figure 39(a) and (b): Transdennal fIla and cumulative amount penneated profiles of
flurbiprofen through hunuzn skin in vitro aJterpre-treo.tment with enJumcer as compared
to no enhancer.
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Figure 40(a) and (b): Transdennal flux and cumulative amount penneated profiles of
flurbiprofen through human skin in vitro after pre-treatment with enhancer as compared
to no enhancer.
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7.3.3.9 Statistical Analysis

Between Groups

1.33

7

0.19

Within Groups

0.22

16

0.001

Total

1.35

23

136.8

0.0000

II

II

Dimercaprol

3

0.430 - 0.495

0.462

No Enhancer

3

0.504 - 0.569

0.537

*

Na Thioglycolate

3

0.511 - 0.576

0.544

*

Monothioglycerol

3

0.522 - 0.587

0.554

*

Thioglycolic Acid
Ethyl Ester

3

0.523 - 0.588

0.556

*

Mercaptoethanol

3

0.686 • 0.751

0.718

Cysteamine

3

0.836 - 0.901

0.869

Dithiothreitol

3

1.184 - 1.249

1.217
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7.3.3.10 Discussion

Flurbiprofen was chosen as a model drug because of its lipophilic nature. It was

hypothesized that increasing the permeability of the polar pathway would probably not
cause increases in the permeability coefficient of lipophilic drugs. Nominal changes in
permeation were observed with all of the thiol enhancers with the exception of
dithiothreitol. The average permeation enhancement for all of the enhancers excluding
dithiothreitol was 1.2 fold. The effect of dithiothreitol was a relatively modest 2.3 fold
increase in permeation. The overall results support the above stated hypothesis.
One-way analysis of variance shows that the variance between enhancer groups
is greater, due to at least one enhancer group, than the variance within each group.
Multiple range analysis using 95 % LSD intervals shows no difference between no
enhancer, sodium thioglycolate, monothioglycerol, and thioglycolic acid ethyl ester. All
other groups were non-homogeneous. Cochran's test for homogeneity of variance shows
homogeneity of experimental error within groups.
Thioglycolic acid ethyl ester, mercaptoethanol, cysteamine, and dimercaprol
significantly reduced the diffusional lag time by an average 73 %. Dithiothreitol reduced
the lag time by one-third. Effects of sodium thioglycolate and monothioglycerol on lag
time were inconsequential.
Thioglycolic acid ethyl ester decreased the time to steady-state by about 70%.
Sodium thioglycolate and monothioglycerol approximately doubled the time to
steady-state. The remaining enhancers had minimal effect.
Although the thiol enhancers were never intended to enhance the permeation of
lipophilic compounds, the ER of 2.3 with dithiothreitol warrants examination of the
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theoretical blood levels obtainable with the use of this enhancer. Using the same system
described with acetaminophen, blood levels after transdermal administration can be
theoretically calculated. The flux of flurbiprofen through human skin in vitro has been
shown by this work to be an average of 18.32 p.g/cm2/hr from a saturated aqueous
solution. If a transdermal system was developed at this thermodynamic activity, at a
patch size of 30 cm2 , and given to a normal adult with an average clearance for
flurbiprofen of 22.5 mlImin (Jamali 1988), the resultant plasma concentration
theoretically should be 0.407 mg/ml (using the standard pharmacokinetic equation that
plasma concentration is equal to the input rate divided by the clearance). Based on the
blood level of 2-3 mg/l seen with a standard recommended dosage regimen (Smith 1989),
therapeutic activity would not be achieved.

With the enhancer dithiothreitol, the

permeation increase of 2.3 fold gives a new flux of 41.51 p.g/cm2/hr. Using the same
transdermal system as previously described, the enhanced plasma concentration would

theoretically be 0.922 p.gl ml, a level near half the therapeutic goal. Further modification
of formulation variables could probably attain systemic therapeutic efficacy.
Surprisingly, one of the thiol enhancers exhibited a negative correlation with
permeation enhancement.

Dimercaprol reduced the permeability coefficient of

flurbiprofen by 14%. This decrease in permeation rate was observed with replicate
experiments and was statistically significant (p < 0.05). Specific experimentation would
be required to ascertain the reason(s) for this phenomena.
The results from this study suggest that for lipophilic drug molecules similar to
flurbiprofen with respect to physicochemical attributes i.e. aqueous solubility of 0.034
mg/ml and oil/water partition coefficient of 88, profound increases in permeation may
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not be possible using one of the thiol enhancers. These results support the theory that

the thiol enhancers, as a class, affect the polar keratinaceous pathway.

178
7.3.4 Xanthine Series
7.3.4.1 DyphyJllne with Thioglycolic Acid Ethyl Ester
TABLE 33: The effect of thioglycolic acid ethyl ester on the pharmacoldnetic and
physicochemical parameters of transdermal dyphylline.
The values in brackets are the standard deviations.

~~I_i~I~~_~QI.I~
Diffusional Lag Time
(hours)

0.800
[0.200]

0.733
[0.208]

Time to Steady-State
(hours)

4.200
[0.265]

1.933
[0.513]

Steady-State Flux
(p.g/cm2/br)

0.197
[0.021]

0.901
[0.050]

Permeability Coefficient (P)
(cmlhr X 10-')

1.64
[0.178]

7.50
[0.420]
4.567

Enhancement Ratio
(p{Fnhattr«}/P{No Fnbancer})
Cumulative Amount Permeated
(p.g/cm2/ day)

[0.256]
2.640
[0.607]

15.008
[1.569]

The lag time for the diffusion of dyphylline through human stratum corneum was
an average of 0.8 hours. The flux gradually increased over the next 3-4 hours, reaching
steady-state at an average of 4.2 hours. From this point forward, the zero-order drug
input rate was an average of 0.197 pg/cm2/hr. ·An average apparent diffusivity of 3.18
X 10-7 cm2/hr was calculated from Fick's law (Eq. 20) and the oil/water partition
coefficient.

The average steady-state flux of 0.197 pg/cm2/hr results in an average

permeability coefficient of 1.64 X 10-' em/hr. The cumulative amount permeated in 24
hours was an average of 2.640 pg/cm2.

Thioglycolic acid ethyl ester significantly increased the permeability coefficient
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of dyphylline by 4th fold (ER=4.567). The average lag time was reduced, but not
significantly. The time to steady-state was significantly reduced by about half to

an

average of 2 hours. The average steady-state flux and cumulative amount permeated at
the end of 24 hours were correspondingly increased by 4112 fold. The results show
conclusively that the permeability of the skin to dyphylline can be significantly increased

by pre-treatment of the skin with thioglycolic acid ethyl ester.
represented graphically in Figure 43(a) and

(b).

These results are
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Figure 43(a) and (b): Transdennal flUX and cumulative amount permeated profiles of
dyphylline through human skin in vitro after pre-treatment with enhancer as compared
to no enhancer.
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7.3.4.2 Caffeine with Thioglycollc Acid Ethyl Ester
TABLE 34: The effect of thioglycolic acid ethyl ester on the pharmacokinetic and
physicochemical parameters of transdennal caffeine.
The values in brackets are the standard deviations.

Diffusional Lag Time
(hours)

1.567
[0.252]

0.933
[0.252]

Time to Steady-State
(hours)

2.800
[0.200]

2.833
[0.802]

Steady-State Flux
(p.gl cm2Ihr)

0.084
[0.021]

0.233
[0.013]

Permeability Coefficient (P)
(cmlhr X 1O~)

4.50
[1.13]

12.5
[0.698]

Enhancement Ratio

2.759
[0.154]

(p{Fnhancer}/P{No EDbancer})

Cumulative Amount Permeated
(p.g/cm2/day)

0.893
[0.210]

4.539
[0.505]

The flux of caffeine through human stratum corneum (no enhancer) exhibited an
average diffusional lag time of approximately I1h hours. Steady-state was reached at an
average of 2.8 hours leveling off at an average drug input rate of 0.084 ,.,.g/cm2/br. This
results in an average apparent calculated diffusivity of 7.92 X 10-7 cm2/hr (using the
oil/water partition coefficient) and an average permeability coefficient of 4.50 X 10-'
em/hr. The cumulative amount permeated in 24 hours was an average of 0.893 ,.,.g/cnr.
Thioglycolic acid ethyl ester significantly increased the permeability coefficient
of caffeine by almost three fold (ER=2.759). The time to steady-state was unaffected.
However the average lag time was reduced by 40 %. There was a corresponding increase
in the average steady-state flux and cumulative amount permeated at the end of 24 hours

by almost three fold. The results show conclusively that the permeability of the skin to
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caffeine can be significantly increased by pre-treatment of the skin with thioglycolic acid
ethyl ester. These results are represented graphically in Figure 44(a) and

(b).
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Figure 44(a) and (b): Transdermal flUX and cumulative amount permeated profiles of caffeine
through hwnan skin in vitro after pre-treatment with enhancer as compared to no enhancer.
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Pre-treatment of the skin with thioglycolic acid ethyl ester results in a slightly increased
permeability coefficient of theophylline. These results are represented graphically in

Figure 45(a) and

(b).
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Figure 45(a) and (b): Transdermaljlux and cumulative amount permeated profiles oftheophylline
through human skin in vitro after pre-treatment with enhancer as compared to no enhancer.
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7.3.4.4 Theobromine with Tbioglycolic Acid Ethyl Ester
TABLE 36: The effect of thioglycolic acid ethyl ester on the pharmacokinetic and
physicochemical parameters of transdermal theobromine.
The values in brackets are the standard deviations.
.

1<

,

... "._.
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:::?OataTab.le» . . .

I

No Enhancer:

I· •.

.20%· Erihancer

Diffusional Lag Time
(hours)

0.633
[0.252]

0.500
[0.200]

Time to Steady-State
(hours)

4.067
[0.404]

1.567
[0.252]

Steady-State Flux
(jLg/cm2/hr)

0.323
[0.021]

0.338
[0.052]

Permeability Coefficient (P)
(cm/hr X 104 )

7.43
[0.483]

7.78
[1.18]

Enhancement Ratio

1.046
[0.091]

(p{Eobancer}/P{No Enb8Dcer})

Cumulative Amount Permeated
(p.g/cm2/day)

.iil

5.135
[0.430]

5.617
[1.241]

Without the effect of any enhancer, theobromine took an average of 0.633
hours to diffuse through human skin in vitro. A steady-state permeation rate of 0.323
pg/cm2/hr was reached at about four hours. An average apparent diffusivity of 1.30 X

10-4 cm2/hr was calculated using Eq.20 and the oil/water partition coefficient.

An

average permeability coefficient of 7.43 X 10-4 cm/hr was calculated using the measured
steady-state flux.

The cumulative amount permeated in 24 hours was an average of

5.135 jLg/cm2.
Thioglycolic acid ethyl ester did not significantly change the permeation rate of
theobromine (ER = 1.046) or the average lag time.

However the average time to

steady-state was significantly decreased by 60 %. Insignificant change in the permeability
results in insignificant change in the average steady-state flux and cumulative amount
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permeated at the end of 24 hours. The results show that the permeability of the skin to
theobromine was not increased by pre-treatment of the skin with thioglycolic acid ethyl
ester. These results are represented graphically in Figure

46(a)

and

(b).
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ANSWERS TO aRB> APPENDIX A

Section IT. Human Subjects.

No. I.' The number of volunteers are expected to be 10-30 with an age range of 20-30

years, not limited to sex, with a caucasian ethnic background. The subjects' health must
be normal (as determined by subjective questioning) specifically with no known or

observed skin rash, eczema, irritation, excessive dryness, known hypersensitivity to
topically applied substances, lack of epidermal intactness, or the like.

No.2: No specimens or samples of any sort will be taken.

Data will consist of

documentation of gross macroscopic changes to the epidermis evident upon visual
observation and consist of erythema, edema, and generalized primary irritation. Data
will be obtained specifically for research purposes.

No.3.' Subjects will be recruited from a group personally known by the Investigator

and chosen by him based on their understanding of the study, character, willingness,
cooperativity, and ability to follow protocol.

Consent will be documented via an

Informed Consent Agreement describing the study procedure and potential risks and
hazards.

HR# 3893-R
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No.4: Potential risks include possible transient localized physical discomfort at the site
of application. The discomfort may take the form of cold or cool sensations, warm or
burning sensations, tingling, prickly, or itching sensations.

These symptoms are

expected to be mild in nature and transient. No psychological, social, legal, or other
risks are expected to occur.

There are no alternative treatments that may be

advantageous to the subject.

No.5: The subjects will have immediate access to and freedom at their own desire to
wash the application site with soap and water at any time during the study, thereby
terminating any potential or realized risks. There is no risk to confidentiality.

No.6.' The risks described above are expected to be localized, mild, and transient.

These risks are relatively reasonable in comparison to the knowledge gained on the
inherent irritation potential of the compounds to be tested. The benefits gained from this

study will determine which compounds can be further studied as components in
formulations of pharmaceutical products designed to be administered through the skin.
This method of drug administration is called controlled transdermal drug delivery and for

many drugs provides a less toxic, more effective, and safer method of delivery.
Transdermal drug delivery provides zero-order controlled delivery of the active agent
over an extended period of time significantly reducing the frequency of dosing. This is

extremely valuable for drugs with short half-lives, where the elimination of the
inconvenience of frequent dosing substantially improves patient compliance. Zero-order

HR# 3893-R
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controlled release also avoids fluctuations in blood levels seen with intermittent dosing.
Fluctuations into the toxic level are the most common cause of adverse drug reactions.
For this reason controlled release is important for drugs with a narrow therapeutic range.
Transdermal administration avoids a multitude of problems encountered with many drugs
administered orally. Poor or uneven oral absorption will cause undesirable blood level
fluctuations, such as that seen with the extent of food intake and various g.L transit

times. The drastic changes in pH along the g.i. tract adversely affect many drugs, such
as degradation by stomach acid or acid-catalyzed hydrolysis in aqueous media. Orally

administered drugs are also subjected to a "first pass effect" in the liver which can
dramatically metabolize the drug thus reducing drug effectiveness.

Since extensive

metabolism is diminished, an equivalent therapeutic effect can be elicited with a lower
total daily dose when given transdennally. In addition, the time available for drug
absorption is limited and controlled by g.i. transit time.
eliminated with transdermal drug delivery.

All these problems are

Lastly, once a drug is swallowed (or

injected) it is very difficult to remove in the event of toxicity or adverse reactions. In

comparison, termination of therapy of a transdermal system is accomplished swiftly by

simply removing the patch.
Transdermal drug delivery systems cannot be developed until the components of
the system have been shown to be non-irritating, thus demonstrating the necessity of this
study.
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Section m. Lay Description.

The purpose of this study is to evaluate the potential toxicity of a select group of
a specific class of chemical substances applied to the skin. Toxicity can manifest itself
in the form of erythema (redness), edema (swelling), or irritation (coldness, burning,

itching, etc.). In order to limit the overall potential risks, the substance is applied in a

minute amount (one drop) and that area is closely observed for changes described above.
If the substance is too discomforting to the subject, it can be washed quickly and
thoroughly with soap and water.

The knowledge gained from this study will determine which compounds can be
further studied as components in formulations of pharmaceutical products designed to be
administered through the skin. This method of drug administration is called controlled
transdermal drug delivery and for many drugs, provides a less toxic, more effective, and

safer method of delivery. Transdermal drug delivery provides controlled release of the
active agent over extended periods of time significantly reducing the frequency of dosing.
This is extremely valuable for drugs with short half-lives, where the elimination of the

inconvenience of frequent dosing substantially improves patient compliance. Controlled
drug input also avoids fluctuations in blood levels seen with intermittent dosing.
Fluctuations into the toxic level are the most common cause of adverse drug reactions.
For this reason controlled release is important for drugs with a narrow therapeutic range.
Transdermal administration avoids a multitude of problems encountered with many drugs
administered orally_ Poor or uneven oral absorption will cause undesirable blood level
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fluctuations, such as that seen with the extent of food intake and various g.i. transit
times. The drastic changes in pH along the g.i. tract adversely affect many drugs, such
as degradation by stomach acid. Orally administered drugs are also subjected to a "first
pass effect" in the liver which can dramatically metabolize the drug thus reducing drug
effectiveness. Since extensive metabolism is diminished, an equivalent therapeutic effect

can be elicited with a lower total daily dose when given transdermally. In addition, the
time available for drug absorption is limited and controlled by g.i. transit time. All these
problems are eliminated with transdermal drug delivery.

Lastly, once a drug is

swallowed (or injected) it is very difficult to remove in the event of toxicity or adverse
reactions.

In comparison, termination of therapy of a transdermal system is

accomplished swiftly by simply removing the patch.
If the compounds of interest prove to be non-irritating, they can be further tested
as permeation enhancers to deliver drugs through the skin thereby taking advantage of
the transdermal route of administration.

Section IV. Informed Consent.

A proposed informed consent is provided in the following five pages.

HRH 3893-R
MEDICAL UNIVERSITY OF SOUTH CAROLINA
INFORMED CONSENT AGREEMENT

I,
, do hereby consent to participate in a study conducted by
Robert M. Bennett for the purpose of observing the toxicity and irritation of various
chemical substances applied to my skin surface. Mr. Bennett has explained orally to me,
as described below, and I fully understand the following:
A. PROCEDURES: I will be subjected to exposure to the intact epidermis of the
forearm a volume of 0.01 ml. (one drop) or less with one or more of the following
compounds:
Thioglycolic acid ethyl ester
Sodium thioglycolate
Mercaptoethanol
Dithiothreitol
Cysteamine
Dimercaprol
Monothioglycerol
Ethanol
Normal saline

Total area of exposure should not exceed one square centimeter. No rubbing or touching
of the application site will be done; the compounds will be allowed to spread and dry on
their own. No one area will be tested twice and if a second study is deemed necessary,
it will not commence until all skin areas have returned to normal. No medication,
anesthetics, or tranquilizers will be used. No injections will be made. No compensation
is offered.
B. DURATION: Application will take approximately 15 minutes. Physiological
parameters to be measured at 0,1,2,24,48 and 72 hours are edema, erythema, irritation,
and irritability . Observation will be made at these times. I will avoid touching, rubbing,
or scratching the application area. I will allow no other compounds or chemicals (except
water) to come into contact with the application area. I will avoid washing of the
application area for 48 hours (unless too discomforting). I will avoid prolonged sun

exposure of the application area.
(see Pa&e 2)
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c. possmLE DISCOMFORT AND/OR RISKS; Toxicity can manifest itself in the
form of erythema (redness), edema (swelling), or irritation (coldness, burning, itching,
etc.). In order to limit the overall potential risks, the substance is applied in a minute
amount (one drop) and that area closely observed for changes described above. If the
substance is too discomforting I can wash my arm quickly and thoroughly with soap and
water that will be readily available to me.

HAZARD POTENTIAUKNQWN TOXICITY INFORMATION

1. 1hioglycoJates (Ihioglycolic acid ethyl ester and Sodium thioglycolate)
Thioglycolates have had extensive and widespread topical use for many years as
solutions for permanent waving of hair. Thioglycolic free acid (not used in the study)
is a primary skin irritant but thioglycolate derivatives show no such irritations after
contact periods from four to 96 hours. Sensitization tests of 162 persons showed no
allergenic responses. The allergenic properties of thioglycolic acid and thioglycolates as
measured by repeated patch tests were appraised as low or non-existent. Beauticians,
who are constantly exposed to thioglycolates in their work, may show a positive response
for contact dermatitis.
2. Cysteamine
Cysteamine has been shown to have the ability to protect tissue from damage to
radiation exposure. Cysteamine also decreases liver toxicity caused by acetaminophen
(Tylenol~) overdosage. Cysteamine injected into the body has been shown to cause
duodenal ulcers, yet it also has been shown to protect the stomach from damage caused
by drinking alcohol. None of these actions are anticipated due to the minimal topical
exposure employed in this study. Cysteamine does not cause hypersensitivity when tested
in animals.

3. Mercaptoethanol
Undiluted 2-mercaptoethanol is mild to moderately irritating on topical application
to normal skin of rabbits but this effect is short-lived.
4. Dimercaprol
Dimercaprol is marketed in the U.S. and abroad as an injectable indicated for the
treatment of arsenic, gold, and mercury poisoning. On the skin of man or animals,
dimercaprol causes localized erythema and edema but no tissue damage or blistering.
Some sensitization has been reported in humans.
(see Pa&e 3)
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5. Dithiothreitol
Dithiothreitol has been used to reverse acetaminophen (Tylenol-) liver damage
caused by overdosage. In a study on the ability of dithiothreitol, L-Cysteine, and
N-Acetylcysteine (currently marketed as Mucomyst'l by Mead-Iohnson Pharmaceuticals
for bronchopulmonary diseases and complications) to break up excess mucous in the
lungs, dithiothreitol was most effective and had the least irritant effect. Skin soaked in
dithioerythritol (an isomer) solution for six hours showed no damage to skin components.
6. Monothioglycerol
Monothioglycerol has been used in veterinary medicine to promote wound
healing. Injections into hamsters caused temporary sterility. Monothioglycerol is four
to six times less toxic than dimercaprol. When applied to rabbit skin six days a week
for two months, no gross abnormalities were found upon autopsy with the exception of
locaHred tissue damage at the site of application and mild enlargement of the thyroid
gland.

General Statements:
No reports of anaphylaxis were found in the literature on any of the above stated
compounds. Some of these compounds have not been tested for allergenicity in humans.
There is a possibility, as with all substances, of an allergic reaction.

Many of these compounds are of a chemical class that may produce an unpleasant odor.
Excessive exposure to the eyes of the vapors of some of these compounds may be
irritating and produce heavy tearing.

References are available upon request.

D. POSSmLE BENEFITS: The knowledge'gained from this study will determine which
compounds can be further studied as components in formulations of pharmaceutical
products ultimately designed to benefit mankind by allowing the administration of drugs
by a less toxic, more effective, and safer method.
E. ALTERNATIVE METHODS: There are no alternative methods of obtaining this

information.

HR# 3893-R

M.U.S,C.
(Paee 4)

Robert M, Bennett (803-792-8430) has agreed to answer any inquiries that I may have
concerning the procedures and has informed me that I may also contact the Medical
University of South Carolina Institutional Review Board for Human Research
(803-792-4148) directly concerning the research study and research subjects' rights. This
Board administers the agreement with the United States Department of Health and Human
Services/Office for Protection (OPRR) covering the protection of human subjects
(#M-I012).
I understand that in the event of any injury resulting from the research procedures to the
participant, reasonable medical treatment not otherwise covered by third party payments
will be available free through the Medical University; financial compensation is not
available for medical treatment elsewhere, loss of work, or other expenses. I may

contact the Medical University of South Carolina Hospital Director (803-792-3932)
concerning medical treatment.
I understand that the participant's records of participation in this study are not accessible
to the general public and confidentiality will be maintained. Information that may be
gained from this study will be used only for research and educational purposes.
Information may be published with permission of the principal investigator in medical
journals, but the participant's identity will not be revealed. However, identifying
information will be available to monitors from the M.U.S.C. IRB for Human Research,
and the u.s. Food and Drug Administration.
It is understood that participation is totally voluntary, and I may choose not to
participate. I also understand that I am free to withdraw my consent and discontinue
participation at any time . Discontinuation will in no way jeopardize the participant's
ability to receive treatment now or in the future at this Institution.
I can attest beyond reasonable doubt that I am not pregnant nor breast feeding.

I understand that no record of my participation or discontinuation will be a part of my
academic record of this Institution. Also, my participation or discontinuation will not
constitute an element of my academic performance .
I understand that any new information that is developed during the course of this study
will be made available to me.
(See

Pa~e

5)
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I will receive a copy of this informed consent after it has been read, understood, and

signed.

Investigator Obtaining Consent

Signature of Participant

Witness

Witness

Date of Consent

Signature of Legal Guardian
(if applicable)

(Consent form reviewed and approved by M.U.S.C. IRB for Human Research:S/1519Q)
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Section V. Experimental Protocol.

In partial fulfillment of the Ph.D. degree the following study is required.
Dennal Toxicity Study of Thiol Compounds

2. RESEARCH PLAN

A. Specific Aim
The objective of this study is to determine the irritation potential of a select group
of a specific chemical class of substances applied topically to normal intact skin. The

broad, long term objective is to isolate specific chemical substances that can be clinically
used as absorption promoters or enhancers for topically applied drugs.

B. Background and Significance

Current topical drug delivery systems are limited to substances exhibiting natural
skin penetration through passive diffusion. These substances are low molecular weight,
highly potent agents possessing a certain degree of hydrophilicity as well as lipophilicity.
These limitations are dictated by the outermost layer of the skin, known as the stratum

corneum, which acts as a barrier. The stratum corneum consists mostly of the protein
keratin.

The barrier strength of keratin is attributed to its extensive disulfide bond

cross-linking. To expand the spectrum of topical drug candidates this keratin barrier

must be overcome. Thioglycolates react with the disulfide linkages of cystine units in
the keratin protein forming sulfhydryl-terminated cysteine units and diminishes the
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number of cross links between polypeptide chains. It has been shown in vitro that this
weakens the keratin and increases its permeability by opening up the stratum corneum
for facile diffusion of drug molecules that previously could not pass or could do so only
minimally. The overall research effort focuses on the use of thioglycolates and other low
molecular weight primary aliphatic thiol compounds as permeation enhancers or
absorption promoters. One of the requirements of a permeation enhancer is that it be
relatively non-toxic i. e. non-irritating to the skin.. This study is designed to evaluate the
acute topical irritation potential of minute quantities of the proposed permeation
enhancers. This information is essential in the overall evaluation of this research effort
in the field of dermatopharmaceutics.

C. Preliminary Studies
Preliminary studies were completed on hairless guinea pigs according to the
following protocol submitted to the M.U.S.C. Animal Review Committee (ARC) .

Title: Acute Non-invasive Dermal Toxicity Study
This study will be in accordance with the method of Draize (1) et
al, Specifically, two male nude guinea pigs (Charles River) approximately
400-500 grams in weight and 30-50 days old (mature) will be used for

exposure to the intact epidermis of the back area for a 24 hour period (or
less) with one or more of the following compounds:
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Thioglycolic acid ethyl ester
Sodium thioglycolate
Mercaptoethanol
Dithiothreitol

Cysteamine
Dimercaprol
Monothioglycerol
Ethanol (positive control)
Normal saline (control)

Compounds will be placed applied directly or in a gauze circular patch of
19-25mm diameter. Total area of exposure will not exceed 10 square

centimeters. Physiological parameters to be measured at 0,1,2,24,48 and
72 hours are edema, erythema, irritation, and irritability. No one area
will be tested twice and a if a second study is deemed necessary, it will

not commence until all skin areas have returned to normal. No injections
will be made. No medication, anesthetics, or tranquilizers will be used.

Veterinary care, food, and housing will be provided by the Department of
Laboratory Animal Resources (DLAR).

(End of study protocol)
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RESULTS OF ANIMAL STUDIES:
Irritation reactions were judged by visual observation. Sensation or sensitivity
was determined by the behavior of the animal. Draize numbers are toxicity ratings
according to the method of Draize et al, (1944).

IMMEDIATE PRIMARY REACI10N after application of one drop of test substance

applied undiluted, as ethanolic, or aqueous solutions. Results are expressed as observed
irritation and sensitivity over a six hour period.

Ethanol

1()() %

No reaction! No sensation

Thioglycolic Acid
Ethyl Ester

100%

At 15 min. blanching with red border.
Very mild. (Draize AI).

Thioglycolic Acid
Ethyl Ester

20%

No reaction! No sensation

Mercaptoethanol

100%

At 45 min. erythema (Draize A2).

Dimercaprol

100%

At 6 hr. erythema (Draize A2),
Slight sensation.

Dithiothreitol

0.25%

No reaction! No sensation

Cysteamine

10%

No reaction! No sensation

Na Thioglycolate

10%

No reaction! No sensation

Monothioglycerol

100%

No reaction! No sensation

ONE HOUR PRIMARY REACI70N after application of test substance for one hour using
a 19 mm (0.2 ml capacity) Hill Top(l gauze patch. Results are expressed as observed
irritation and sensitivity upon removal of patch.
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Ethanol

100%

Slight drying of skin.

Thioglycolic Acid
Ethyl Ester

100%

Blanching.

Mercaptoethanol

100%

Erythema (Draize A2).

Dimercaprol

100%

Blanching.

Dithiothreitol

0.25%

No reaction! No sensation

Cysteamine

10%

No reaction! No sensation

Na Thioglycolate

10%

No reaction! No sensation

24 HOUR PRIMARY REACI'lON after application of test substance for 24 hours using
a 19 mm (0.2 ml capacity) Hill Top· gauze patch. Results are expressed as observed

irritation and sensitivity upon removal of patch .
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Ethanol

100%

Dry skin.

Thioglycolic Acid
Ethyl Ester

20%

Moderate erythema (Draize A3).
Peeled stratum corneum.

Thioglycolic Acid
Ethyl Ester

10%

No reaction/ No sensation

Dithiothreitol

0.25 %

Dry skin.

Mercaptoethanol

100%

Blistering. Blanching. Capillary breakage.
Scarring. Erythema (Draize A4).

Cysteamine

Sat.Solo

Slight blistering. Erythema (Draize A3).
Capillary breakage.

Dimercaprol

100%

Erythema (Draize A2).

HR# 3893-R

M.U.S.C.

Reference:
Draize, I.H., G. Woodard, H.O, Calvery, "Methods For The Study of Irritation and
Toxicity of Substances Applied Topically to the Skin and Mucous Membranes". The
Iournal of Pharrnacolo&y and Experimental Therapeutics. 82; 377-390, 1944.

Discussion.'
Toxicity manifestations of concern to this application are those seen with

IMMEDIATE PRIMARY REACI10N.

If toxicity was observed, it consisted of color

changes only. Only one compound (mercaptoethanol) had significant erythema (Draize
A2

= Well defined erythema).

Thioglycolic acid ethyl ester indicated blanching with

an erythematous border (Draize Al

= Very slight erythema that is barely perceptible).

Most compounds showed no reaction or sensation.
Toxicity seen with ONE HOUR PRIMARY REACI70N was minimal. Maximum
toxicity was seen with mercaptoethanol and consisted only of erythema not exceeding a
rating of Draize A2.

(end of animal study)
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D. Etperimenral Design and Methods
This study is designed to evaluate specific low molecular weight primary aliphatic
thiols (listed below) applied topically to the forearm of normal adult non-pregnant,
non-breast feeding volunteers, The number of volunteers is expected to be 10 to 30 with
an age range of 20-30 years, not limited to sex, with a caucasian ethnic background.

The subjects' health must be normal (as determined by subjective questioning)
specifically with no known or observed skin rash, eczema, irritation, excessive dryness,
hypersensitivity to topically applied substances, lack of epidermal intactness, or the like.
The intact epidermis of the forearm will be exposed to a volume of 0.01 ml (one drop)
or less (applied with a standard TB syringe or micropipet) of one or more of the
following compounds:
Thioglycolic acid ethyl ester
Sodium thioglycolate
Mercaptoethanol
Dithiothreitol
Cysteamine
Dimercaprol

Monothioglycerol
Ethanol (positive control)
Normal saline (control)
All subjects may receive any or all test compounds.

Total area of exposure

should approximate but not exceed one square centimeter. No rubbing or touching of
the site will be done upon application; the compounds will be allowed to spread and dry
on their own. No one skin area will be tested twice and a if a second study is deemed
necessary, it will not commence until all skin areas have returned to normal.

No

medication, anesthetics, or tranquilizers will be used. No injections will be made. No
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compensation is offered. Volunteers will be required to read, understand, and sign an
informed consent form.
The results of this study will be evaluated in accordance with the method of

Draize et al (1944), Physiological parameters to be observed at 0,1,2,24,48 and 72
hours after application are edema, erythema, irritation, and irritability. Subjects are
requested to avoid touching, rubbing, or scratching the application area and to allow no
other compounds or chemicals (except water) to come into contact with the application
area. Subjects are also requested to avoid washing of the application area for 48 hours
(unless too discomforting) and to avoid prolonged sun exposure of the application area.

Only gross macroscopic changes will visually observed; no cellular or tissue components
or specimens will be taken.

HA~PO~/KNOWNTO~CITYThWORMATION

1. Thioglycolates (Thioglycolic acid ethyl ester and Sodium thioglycolate)
McCord (1946), in an exhaustive paper on thioglycolates and their use as
solutions for permanent waving of hair, conducted tests with thioglycolic acid and other
thioglycolates. The tests included patch tests for primary skin irritations and tests for
allergic sensitizations. The results show that thioglycolic acid (not used in the study) is
a primary skin irritant at relatively low concentrations (approximately 2.8%). Sodium

thioglycolate (based on 3.52 % thioglycolic acid) showed no positive results after contact
periods from four to 96 hours, nor did sodium thioglycolate (based on 4.6% thioglycolic
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acid) show positive results under 24 hours, but longer exposures showed occasional
positive responses.

Thioglycolates in cream form up to 7.13 % induced no positive

responses from four, six, and nine hour contact periods, however results from longer
periods are shown in Table I.

Table I
Results from Patch Tests 7.3% Sodium Thioglycolate
(Cream Form), Prolonged Exposure
(Adapted from McCord 1946)

Number

Contact Time(br)

No, Pos.

182

24

16

51

48

14

72
96

7
2
7

12

Percent

8.0
13.7
14.3
58.3

Individuals may become sensitive to almost any substance with most compounds
inherently possessing various degrees of allergenicity. A few select compounds have a
proven capacity to establish a state of allergic sensitivity. McCord's (1946) sensitization
tests of 162 persons showed no positive responses to thioglycolates in the absence of a
like initial response. The allergenic properties of thioglycolic acid and thioglycolates as

measured by repeated patch tests were appraised as low or non-existent
An extensive skin sensitization study by Voss (1958) concluded that thioglycolic
acid was devoid of significant allergenic activity in tests on 60 subjects.
In a case report by Storrs (1984), eight hairdressers and four clients were found
to be allergic to glycerol monothioglycolate (not used in this study) in "acid" permanent
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waves. He reports that in contrast, ammonium thioglycolate and other thioglycolates
have been used since 1943 in cold "a1kaline" permanent waves both in homes and salons
with no clearly documented cases of contact allergy.

In a report by Wickett (1987), he states that permanent waves "generally rely on

high alkalinity to break the bonds and reform them with acid. Problems with permanent
waving are usually due to over-treatment or under treatment of the hair, rather than
allergy or irritation. Straighteners can be irritating because o/their high alkalinity."
In a study by Matsunaga (1988) using 5% aqueous solutions of ammonium

thioglycolate, three out of seven beauticians showed a positive response for contact
dermatitis.

After exposure of rabbits' skin to a daily application of 0.6 N ammonium
thioglycolate (PH 9.3) for 20 days, 6.5 mVkg/day was determined to be innocuous
(Kauder 1983).
Sodium thioglycolate was rated non-carcinogenic as a result of a study in which
1% and 2 % solutions in acetone were applied to the shaved skin of mice and rabbits
twice weeldy during the lifetime of the animals (Kauder 1983).
Upon intraperitoneal injection of thioglycolic acid ethyl ester in the rat, the LDso

was reported as 176 mg/kg. No toxicity effects were noted. With oral administration
to the rat, the LDso was reported as 178 mg/kg. No toxicity effects were noted (Schmidt
1974). Intraperitoneal injection of sodium thioglycolate in the rat indicated an LDso of
126 mg/kg. Somnolence and dyspnea were noted. An LDLO of 500 mg/kg was observed
with intravenous injection in dogs. Tremors, g.i. hypermotility, diarrhea, nausea and
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Oral administration to the mouse gave an LDso of 504 mg/kg.

Somnolence and some convulsions were observed (Freeman 1956). Intravenous injection
to the mouse gave an

LD50

of 422 mg/kg. No toxic effects were noted (Ito 1985).

2. Cysteamine

Cysteamine has been shown to have radioprotective capability by protecting,
transforming, and scavenging -OH radicals (Held 1984). Cysteamine also decreases

acetaminophen hepatotoxicity by decreasing the cytochrome P-450 dependent formation
of the toxic acetaminophen metabolite mercatopurate (Miller 1986).

Dunsford and

co-workers (1984) evaluated cysteamine as a potential inhibitor of carcinogenesis. The

data suggested possible tissue-specific anticarcinogenic properties.
Cysteamine subcutaneously is widely used in rodents to induce duodenal ulcers

through a systemic mechanism of gastrin release (Man 1984, McIntosh 1984). Trier and
co-workers (1987) and Mizui and co-workers (1987) independently indicated that
cysteamine has a gastroprotection effect of ethanol induced gastric mucosal damage.

Voss (1958), in an attempt to sensitize guinea pig skin, had 0% sensitized out of five
animals tested.

Upon intravenous injection of cysteamine in the rabbit, the LDso was reported as
150 mg/kg. No toxicity effects were noted. With intraperitoneal injection in the rabbit,
the LD50 was reported to be 232 mg/kg. Here again, no toxicity effects were noted
(Beccari 1955).
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3. Mercaptoethanol
White and co-workers (1973) reported on the toxicity of mercaptoethanol tested

for primary irritation on abraded and unabraded

rabbit

skin.

Undiluted

2-mercaptoethanol was moderately irritating on topical application to both abraded and
normal skin of rabbits. Although the irritation to normal skin was transient, that to
abraded areas was quite long lasting.

Furthermore, primary reactions of a similar

magnitude to ethanol healed much more quickly than those to 2-mercaptoethanol.
Dilutions of 1:5 and 1: 10 of 2-mercaptoethanol produced a moderate, transitory irritation
in abraded skin and only a very slight reaction in normal skin. Edema was of little

significance at any concentration level below 100%.

In summary, he states that

2-mercaptoethanol was only slightly irritating upon topical application to normal skin but
elicited quite severe reactions on exposure to abraded and intracutaneous tissues.
Upon oral administration to the mouse, the LD.so was reported as 200 mg/kg.
Behavioral changes were noted and consisted mainly of excitability.

Respiratory

depression was also indicated. With oral administration to the rat, the LD.so was reported
as 244 mg/kg. Respiratory depression was observed here also (pugaeva 1971).

4. Dimercaprol
Dimercaprol is marketed in the

u.s.

and abroad as an injectable indicated for

arsenic, gold, and mercury poisoning. On the skin of man or animals, dimercaprol
causes localized erythema and edema but no necrosis or blister formation (Waters 1945).
Dilutions still therapeutically active, on the order of 5-10%, completely prevent
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skin lesions caused by lewisite and other vesicant arsenicals. Sulzberger and co-workers
(1946) have reported sensitization in humans.

Intramuscular injection in the human yielded a TDLO of 3 mg/kg, Hemorrhaging
and dermatitis were also noted (Waters 1945), Upon intramuscular injection in the
mouse, the LDso was reported to be 113 mg/kg.

No toxic effects were evident

(Kuschinsky 1954), After intramuscular injection in the rat, the LDso was determined
to be 87 mg/kg. No toxicity effects were noted. (Danie11947). Upon intraperitoneal

injection in the rat, the LDso was found to be 105 mg/kg.

No toxic effects were

indicated (Cheymo11947). An intravenous injection to the mouse yielded an LDso of 56
mg/kg, No toxic effects were observed (Stratford 1984). Intravenous injection in the
rabbit yielded an LD50 of 50 mg/kg. No toxicity effects were noted. (Daniel 1947).

Upon intraperitoneal injection in the rabbit, the LDso was reported as 40 mg/kg. The
toxicity effect observed was an increase in blood pressure. A subcutaneous injection in

the rabbit yielded an LDso of 2 gm/kg (Cheymo11947).

5. Dithiothreitol

Dithiothreitol has been used to reverse acetaminophen hepatotoxicity (Tee 1986),
cadmium-induced hepatotoxicity (Stacey 1986), and partial reversal of mercury-induced
renal toxicity (Klonne 1985).

In a monolayer of Chinese hamster cells low

concentrations (0.4 and 1,0 mM) caused cell killing, but higher concentrations (above
2mM) did not.

In a paper by Lightowler and Lightowler (1971) the mucolytic activity of

HR# 3893-R

M.U.S.C.

dithiothreitol, L-Cysteine, and N-Acetylcysteine was studied. The latter is currently
marketed as

Mucomys~

by Mead-Johnson, Pharmaceuticals for bronchopulmonary

diseases and complications. In treating human respiratory mucus in vitro, dithiothreitol
was shown to be a superior agent for the specific and total reduction in viscosity. A

second objective of the study was to assess, in a suitable animal model, the irritation that
may be caused by the topical application of the stated compounds to the tracheal mucosa
surface. Histopathological examination showed minor or moderate epithelial losses with
fibrinous and polymorph acute inflammatory infIltration with varying degrees of

hemorrhage with all three compounds. The polymorph infiltration was restricted to the
submucosal layer immediately deep to the epithelium without loss of epithelial cells.
Reactions specific to dithiothreitol were dilation of mucosal gland ducts with polymorph
exudate into the dilated glands. These reactions were limited to two rats using 0.01 ml
of 0.1 M and 0.5 M concentrations. In summary, the authors concluded •dithiothreitol

was the most effective mucolytic and had the most favourable minimum effective dose to
minimum irritant ratio and is the drug of choice" .
Kobayasi and co-workers (1977), in a study of the degradation effects on dermal
fibrillar structures of, among other compounds, dithioerythritol (an isomer of
dithiothreitol), found that this compound did not affect collagen fibers at all, transformed
elastic fibrils into smooth-surfaced, dense, beaded strings, and at the dermo-epidermal
junction the anchoring fibrils were unchanged. It should be noted the human skin punch
biopsies were incubated in dithioerythritol solution for six hours as opposed to a one time
application to the outermost stratum corneum only as described in this study.
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In a study by Harber and co-workers (1972) of photoprotection against JKlrphyrin

photosensitization using dithiothreitol, one hundred mice were injected intraperitoneally
with 80 mg/kg body weight of dithiothreitol in a 5.5% glycerol solution. This group
showed a 75% reduction in mortality (p<O.03). No lethal effects were observed in

animals treated with dithiothreitol in the above concentrations without 400 nm of
radiation.
Upon intramuscular injection of dithiothreitol in the mouse, the LDso was reported

as 108 mg/kg. Behavioral changes were noted (Weatherall 1949). The LDso for an
intraperitoneal injection to the mouse was reported as 154 mg/kg. No toxicity effects
were noted (Shinoda 1974).

6. Monothioglycerol
Monothioglycerol has been used in veterinary medicine to promote wound healing
(Windholz 1976).
Subcutaneous injections into hamsters at a dose of 25 mg/kg body weight twice
daily for 5 weeks deprived 4 out of 5 males of their fertility. This was due to a sperm

toxic action rather than a lack of spermatogenesis (Das 1978).
Application of pure monothioglycerol to the clipped skin of rabbit indicates that
20 to 25 times as much is required to produce a systemic effect as when given

intravenously. In both the cat and the rat monothioglyceroI is one-sixth to one-fourth as
toxic as dimercaprol. Repeated topical administration (7.5 % aqueous solution six days
a week for two months) produced mild thyroid hyperplasia, but this was not seen when
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given intraperitoneally. No gross abnormalities were seen in major organs upon autopsy
(Kensler 1949).
Upon intraperitoneal injection of monothioglycerol in the mouse, the LDso was
reported to be 340 mg/kg.

The LDso for intraperitoneal injection in the rat was

determined as 390 mg/kg. Lacrimation and behavioral changes were observed when
given intraperitoneally in the mouse and rat and intravenously in the cat and rabbit
(Freeman 1956).

E. Consultants/Collaborators
No consultants/collaborators are needed for this study. The C.V. of the principle
investigator is included in the appendix.
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G. Facilities Available
A research laboratory (QE-319) will be used to conduct the study. This lab is

located in the Quadrangle building in the Dept. of Pharmaceutical Sciences ofM.U,S.C.

Clinical resources, office space, secretarial and clerical assistance, and emergency
equipment and resources normally available to the department are available for this

study. No major items of equipment are necessary for this study.
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